

REVIEW

Open Access



Beyond the mouse: 3R-guided alternative animal models transforming cancer research

Tobias Faehling^{1,2,3,4} , Tobias Reiff⁵ , Björn Schumacher^{6,7}, Richard Arndt^{1,2,3,8} , James F. Amatruda^{9,10}, Thomas G. P. Grünewald^{1,2,3,11} and Florencia Cidre-Aranaz^{1,2,3*}

Abstract

Comprehensively understanding cancer biology requires complex model systems, typically animal models, to replicate tumor behavior, microenvironment interactions, and cell migration/metastatic processes. Traditionally, genetically engineered and xenograft mouse models have been the cornerstone of cancer research. In recent years, the 3R principle—Replacement, Reduction, and Refinement—has reshaped ethical cancer research by promoting alternative animal models. Here we critically examine *in vitro* and *in silico* as well as four 3R-compliant animal models — the chicken chorioallantoic membrane (CAM) model, *Danio rerio*, *Drosophila melanogaster*, and *Caenorhabditis elegans* — and assess their advantages, limitations, and translational relevance for cancer research. Special emphasis is placed on practical considerations to inform optimal decision-making, including reproducibility and model-specific advantages and challenges. This review aims to support researchers in selecting ethical and effective preclinical models to advance cancer research.

Keywords 3R principle, Cancer modelling, CAM, *C. elegans*, *Drosophila*, Zebrafish

*Correspondence:

Florencia Cidre-Aranaz
florencia.cidrearanaz@dkfz.de

¹Hopp Children's Cancer Center Heidelberg (KITZ), Heidelberg, Germany

²National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany

³Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

⁴Department of Paediatric Oncology, Haematology, Oncology and Immunology, Heidelberg University Hospital, Heidelberg, Germany

⁵Institute of Genetics Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

⁶Institute for Genome Stability in Aging and Disease, University and University Hospital of Cologne, Cologne, Germany

⁷Cologne Excellence Cluster for Stress Responses in Ageing-Associated Diseases (CECAD), University and University Hospital Cologne, Cologne, Germany

⁸Faculty of Medicine, Heidelberg University, Heidelberg, Germany

⁹Cancer and Blood Disease Institute, Division of Hematology-Oncology, Children's Hospital, Los Angeles, CA, USA

¹⁰Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

¹¹Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Introduction and 3R principle

While all animal experimental approaches must be conducted under strict ethical and legal frameworks, and with predefined humane endpoints, the systematic study of animal experimental techniques further led to the proposal of the 3R principle — Replacement, Reduction, and Refinement — in 1959: Replacement, as a proposal to use alternative models instead of animals whenever possible; Reduction, as an effort to minimize the number of animals used per experiment and the overall number of experiments per study; and Refinement, with the purpose of decreasing animal distress and improving their welfare [1]. These principles were introduced to increase the reliability of experiments by reducing the unwanted and uncontrolled stimuli introduced by distress and by concern for the animal's wellbeing itself. More recently, increasing awareness of the broader consequences of animal experimentation—including public scrutiny, ethical responsibility, and the impact of animal mistreatment



© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

on the well-being of scientific staff—has contributed to the tightening of regulatory requirements [2–4]. In this context, the development of a 3R framework and incorporating 3R-compliant models has gained substantial importance in the field of biomedical research [5, 6].

The 3R principle can be readily applied by combining *in vitro* (two-dimensional (2D) and three-dimensional (3D)) and *in silico* modeling. Nevertheless, while these methods are becoming increasingly sophisticated, they still cannot fully recapitulate complex tumor-stroma interactions, immune responses, and metastatic processes, among others [7, 8]. Thus, animal models—usually rodents—remain a cornerstone of basic, physiological, and translational cancer research [9].

In recent years, alternative animal models have experienced a renaissance as viable substitutes or complements to rodent models, since the former are generally perceived as less sentient compared to fully developed rodents [10–12]. Consequently, international regulations consistently exempt invertebrate models (e.g., *Caenorhabditis elegans*, *Drosophila melanogaster*) from animal-use legislation, while vertebrate models like zebrafish and avian embryos become legally protected only beyond certain developmental stages. In Canada, Australia, the UK, and the EU, laws or guidelines protect vertebrates depending on developmental stages (e.g., from the point of independent feeding) and cover avian species only after hatching or late-term incubation, leaving earlier embryos unregulated [13–17]. Similarly, Japan's self-regulation framework omits fish (such as *Danio rerio*, known as 'zebrafish') and invertebrates, focusing on mammals, birds, and reptiles, while China's regulations apply 3Rs-based oversight only to traditional vertebrate laboratory animals [18].

In this context, the most historical non-rodent model discussed in this review is the chick embryo chorioallantoic membrane (CAM) model, with first xenotransplantation studies done in 1911 [19]. In the 1980s, modeling cancer cell invasion and metastasis was first introduced by the pioneering work of L. Ossowski [20, 21]. Similarly, *D. melanogaster* (fruit fly) emerged as a model organism for genetic research, with the first hereditary tumor being described in 1919 [22]. Subsequent landmark discoveries in developmental genetics, most notably the identification of patterning genes recognized by the 1995 Nobel Prize, fundamentally advanced the field [23–25]. These insights laid the foundation for genetically engineering human tumors in *Drosophila* by manipulating oncogenes and tumor suppressors from the 1980s onward [23–27]. Zebrafish emerged as a cancer model in the 1980s, providing a transparent system for live imaging and high-throughput drug screening [10, 28–31]. Further, cancer research on *C. elegans* began with the discovery of apoptosis-regulating genes in the 1970s and 1980s, eventually

leading to the Nobel Prize in 2002 [32, 33]. Thus, this review will focus on these frequently used and flexible alternative animal models: avian embryos, fruit fly, zebrafish, and the nematode worm *C. elegans* [11, 34, 35].

Advances in imaging, genetic manipulation, and micro-environmental engineering have enhanced the reliability and applicability of these models [36]. Moreover, the advent of personalized medicine—mostly relying on cell culture or murine PDXs—has further driven the development of patient-derived models that better mimic human cancers while aligning with the 3R principles [37]. This renewed interest reflects a broader paradigm shift in preclinical research, where integrating alternative model organisms with traditional approaches may enhance the success of basic and translational cancer studies.

This review presents 3R-compliant alternative models and comparatively discuss their strengths and limitations, facilitating the selection of ethical and effective preclinical models to advance cancer research.

Non-animal models

In silico modeling of cancer

In silico modeling of cellular behavior and cancer progression offers the possibility to conduct a high number of experiments in parallel, elucidating many potential pathophysiological and pharmacological parameters. Aggregating data from different patients or even cancer types to simulate tumor growth, invasion, angiogenesis, and immune interactions integrated with clinical data may aid in refining hypotheses and optimizing therapeutic strategies, thus aligning with the Reduction principle [38, 39].

Structural bioinformatics and molecular dynamics simulations enable detailed modeling of protein folding, stability, and interactions, supporting antibody discovery and the engineering of cellular therapies by predicting antigen-binding and receptor-ligand dynamics [40]. The integration of clinical datasets into artificial intelligence (AI)-driven modeling frameworks further advances the development of personalized medicine, allowing prediction of patient-specific treatment responses, resistance mechanisms, and disease progression [41, 42].

Although ongoing improvements in machine learning, data integration, and biophysical modeling have markedly enhanced *in silico* models, it should be noted that they represent a simplification of the biological complexity of cells and organisms, and their predictions still require experimental validation [41, 42].

Conventional 2D cell culture

Preclinical oncology has significantly advanced through the use of established tumor cell lines, especially due to their ease of handling, low cost, and broad availability [43]. Culturing cell lines in 2D enables the controlled

investigation of drug response, proliferation, migration, and phenotypic plasticity under standardized conditions [44, 45]. However, 2D cultures cannot replicate the complex 3D architecture, biochemical gradients, or cell-matrix interactions present in tumors. In addition, their potential clonal evolution may result in limitations in experimental reproducibility [46, 47]. As a result, their predictive value for *in vivo* tumor behavior and therapeutic response studies is limited, highlighting the need for more physiologically relevant models in translational cancer research [48–50].

Physiological 3D or organoid cell culture

3D cell culture technologies better mimic the cell states *in vivo* by enabling physiological cell-cell and cell-matrix interactions [51, 52]. Tumor spheroids and patient-derived organoids preserve key features such as tumor heterogeneity, tissue-specific architecture, and nutrient and oxygen gradients, supporting more accurate modeling of growth dynamics, therapy resistance, and metastatic behavior [52–54]. In addition, organoids retain the molecular profiles of primary tumors, making them valuable platforms for personalized medicine and biomarker discovery [55]. Finally, organ-on-a-chip systems combine 3D cultures with microfluidics to recreate dynamic perfusion, mechanical forces, and complex tissue organization, further allowing real-time monitoring of cancer cell invasion, extravasation, and interactions with stromal and immune cells under controlled conditions [56, 57].

However, despite these advances over two-dimensional cultures, 3D *in vitro* systems remain fundamentally reductionist. They lack integration in systemic cues and fail to recapitulate critical features of full organisms, including tissue-tissue interactions, functional blood and lymphatic circulation, physiological immune composition, endocrine and metabolic regulation, and dynamic chemical and hormonal fluctuations and gradients related to nutrition or circadian rhythms [44, 58–60]. Moreover, they often rely on exogenous, researcher-defined supplementation (e.g., growth factors and matrices), which can substantially shape cellular states and thereby influence tumor cell physiology and therapy responses [61]. While some of these parameters can be partially modeled using organ-on-a-chip or microfluidic platforms, they are typically addressed in isolation, at high technical complexity and cost, and still rely on artificial, plastic-based environments. These limitations are discussed in detail in several comprehensive reviews of 3D cancer models and organoid systems, which underscore their value as intermediate experimental platforms rather than full surrogates of *in vivo* biology [51, 62, 63].

Chorioallantoic membrane model (CAM)

General experimental approach and alternative setups

The CAM model offers a versatile and accessible *in vivo* platform for investigating human tumor biology, metastasis, and therapeutic responses. Since several dozen biological replicates can be feasibly performed in parallel in CAM studies every three weeks, this model is also amenable to studying a high number of biological variables [64].

During early embryonic development, the chorion and allantois fuse to form the CAM, which progressively expands to cover most of the eggshell surface [65]. Due to its important role in gas exchange and metabolism, the CAM develops a dense and highly organized vascular network, while its extraembryonal localization results in a lack of innervation [65–67]. These characteristics provide a permissive, well-perfused environment for tumor growth and manipulation.

Typically, CAM experiments comprise sequential incubation, transplantation, and analysis phases, during which the embryos are maintained under controlled conditions, usually entailing incubation at 37.5 °C and 70–90% relative humidity [66, 67]. After early embryonic development, the CAM is rendered accessible and allowed to mature to a stage permissive for experimental manipulation, including tumor transplantation and co-culture with stromal components [36, 64, 67–70] (Fig. 1A). Human tumor material, including patient-derived fragments or cell suspensions, can be transplanted onto the CAM, optionally in combination with human stromal components such as fibroblasts, endothelial cells, or immune cells to approximate features of the tumor microenvironment (TME) [71]. Using established protocols, high tumor engraftment rates of $\geq 80\%$ can be achieved [36, 64, 68, 72, 73]. Following inoculation, tumor growth can be monitored (see chapter ‘Analysis and experimental readouts’). Finally, tumors are harvested along with the surrounding CAM tissue for subsequent histological, molecular, or functional analyses [69, 74] (Fig. 1A). A collection of detailed step-by-step protocols on each of the aforementioned interventions is already established [36, 64, 67–70].

Several protocol adaptations of the CAM model have been developed to allow for assessment of additional features. These adaptations range from maintaining the eggs in hypoxic conditions to mimicking pathophysiological processes [75] (Fig. 1B). Additionally, for metastasis studies, tumor cells can be recovered from distant sites at the embryo or tracked to investigate dissemination and secondary lesion formation [67]. Moreover, to directly assess the late steps of the metastatic cascade, tumor cells can be injected into CAM vessels so extravasation and metastasis formation can be studied [76] (Fig. 1B). Alternative avian species, such as quail and duck, offer differing




Fig. 1 Overview of avian CAM model. **A.** Timeline for a general experimental procedure. ED: embryonic day. **B.** Schematic representation of alternative experimental procedures, including *ex ovo* assays, intravenous injection, employment of other avian species (chicken egg displayed for reference, scale bar = 35 mm), and different environmental factors that may be controllably modified. **C.** Analysis and data generation. Top, left: Stereomicroscopy with sample image of a CAM-grown Ewing sarcoma primary tumor where the vasculature can be quantified. Top, right: Quantification of migrated cells by qPCR analysis of human-specific Alu-sequences (left). Schematic view of fluorescently marked cells (GFP, green) disseminating in the embryo (right). Bottom, left: Histology of a CAM-grown desmoplastic small round cell tumor stained with H&E (left) and human mitochondria antibody (right). Bottom, right: Functional in vivo imaging of luciferase-transfected cells of a CAM-grown Ewing sarcoma (left: brightfield, right: overlay with bioluminescence imaging (BLI) signal). Created in BioRender (<https://BioRender.com>)

egg sizes and developmental rates, either prolonging the experimental window or improving throughput [77, 78] (Fig. 1B). Interestingly, due to their size, ostrich eggs are compatible with clinical radiological and radiotherapeutic devices and can provide more time and space for experimental manipulation [79].

To enhance both physical and optical access to the embryos, *ex ovo* culture systems have been developed, where embryos are transferred from their shells onto sterile supports at ED 3^{Ref.77}. It should be noted that both ostrich and *ex ovo* models enable the seeding of multiple tumors within a single embryo, facilitating direct comparison of experimental and control groups in a shared microenvironment [78] (Fig. 1B).

Analysis and experiment readouts

Complying with the 3R principle mandates an efficient use of the avian embryos, which requires accurate

tracking and evaluation of tumor characteristics on the CAM [1, 2]. Several hallmarks of cancer, including proliferation, invasion, vascularization, and therapy resistance, can be assessed using a combination of *in ovo* imaging, histopathology, and molecular approaches in the CAM model [80–83].

Cell proliferation and viability can be longitudinally tracked by stereomicroscopy, bioluminescence (BLI), and fluorescence imaging (Fig. 1C). While stereomicroscopy captures the morphology of the transplant and the surrounding CAM, BLI intensity reflects tumor size and viability [80]. Fluorescent proteins or tracking dyes can be employed to achieve stronger signals than BLI or functional read-outs [84, 85]. Importantly, even the development of micrometastases can be detected using fluorescent microscopy in *ex ovo* experiments [86] (Fig. 1C).

Angiogenesis can be quantified by injecting tracers into CAM vessels, which enables analyses of vessel density, morphology, and functional characteristics [87]. To improve reproducibility, deep learning tools, such as the IKOSA platform, can be employed for automatic angiogenesis quantification [87]. Alternatively, laser speckle contrast imaging (LSCI) can measure perfusion dynamics within angiogenic networks [88] (Fig. 1C).

Migration and metastasis can be either analyzed locally by quantifying the invasion of tumor cells in the CAM or systemically by detecting cell dissemination to distant parts of the embryo. Additionally to fluorescence, human-specific Alu PCR can be employed to enable highly sensitive detection of micrometastases in the distant CAM with a detection range of even < 100 cancer cells [67, 89–91] (Fig. 1C).

It should be noted that the CAM is amenable to the use to radiological approaches that mirror those in clinical practice. For instance, similar to BLI, Positron emission tomography (PET) imaging enables viability tracking due to the metabolism-dependent uptake of radiotracers. Moreover, tracers targeting different tumor entities and biological processes are available, and their pharmacodynamics in CAM are comparable to those of murine xenografts [89, 92]. In addition, using ultrasound, tumor growth can be exactly determined and longitudinal analysis of angiogenesis is possible [93] (Fig. 1C).

Finally, several hallmarks of cancer can be assessed by histopathological and deep molecular profiling. Hematoxylin and eosin (H&E) staining, illustrated in Fig. 1C, reveals tumor architecture, stromal invasion, and vascular density. Importantly, CAM xenografts have shown to closely mimic the histomorphology found in patient tumors [64, 68]. Immunohistochemistry (IHC) using universal or tumor-specific human markers vs. avian-specific stainings can be used to distinguish grafted tumors from host tissues, while functional markers may be employed to characterize tumor states [64, 68, 80, 94].

Together, the versatility of readout strategies establishes the CAM model as a powerful and reproducible platform for translational oncology research.

Therapy modalities

The CAM model is compatible with a wide array of therapy strategies commonly used in patients. CAM xenografts enable medium-throughput screening of anti-cancer drugs, including their effects on tumor growth, angiogenesis, and metastatic dissemination [69, 95, 96]. In terms of therapeutic administration, drugs can either be applied topically, injected into the albumen, or intravenously, and different delivery strategies such as antibodies, nucleic acids, nanoparticles, or proteoliposomes are possible [64, 96–100]. Interestingly, avian embryos exhibit a high tolerance to radiation in clinical doses,

making them a feasible model for radiotherapy treatment assessment [101].

Due to the relatively high throughput of CAM experiments, treatment schemes and pharmacological combinations can be readily optimized [102]. In addition, the multiplicity of available drug administration strategies allows for genetic manipulation and gene therapy to be employed, including the use of nucleic acids and tumor-targeting viruses. Indeed, Huang and colleagues showed that overexpression of a tumor-suppressor microRNA in a non-small cell lung cancer xenograft inhibited tumor growth and angiogenesis in the CAM model [103]. Additionally, Krutzke and colleagues used human adenovirus type 5 (HAdV-5) to assess virus–host interactions, biodistribution patterns, and tumor-targeting profiles in the CAM model [104]. However, the embryonic nature of the host imposes important constraints on dosing of many chemotherapeutic or embryotoxic agents, as systemic exposure can rapidly lead to malformations or lethality at concentrations below human-equivalent levels [68, 105]. Consequently, several cytotoxic drugs must be tested at empirically down-titrated doses that prioritize embryo viability over pharmacokinetic matching, limiting the extent to which CAM readouts can be interpreted as quantitatively human-relevant for such compounds [99, 106].

Furthermore, light-based modalities are likewise well suited to the CAM. Kerkhoff and colleagues used 5-ALA-mediated photodynamic therapy in a sarcoma model to disrupt tumor vasculature and induce tumor regression [107]. Owing to the high vascularization of tumor transplants, the CAM model can be used to evaluate angiogenesis inhibitors and vascular disrupting agents. Of note, the ability to conduct live microscopy allows real-time monitoring of angiogenesis, endothelial breakdown and localized hemorrhage [106, 108].

Although the chick embryo has an immature immune system, where no immune cells are present until ED 10–11, it has recently been described that the CAM model can still be utilized for immunotherapy research [109–112]. Indeed, human PD-1/PD-L1 checkpoint blockade in tumor-bearing CAMs significantly slowed tumor growth, and co-implantation of human immune cells or chimeric antigen T-cells with tumors could recreate human-like immune interactions *in ovo* [95, 111, 112].

Overall, the CAM model is an excellent resource to robustly test and combine a wide array of anti-cancer treatment strategies and can aid in bridging the transition from *in vitro* experiments to rodents and ultimately patients.

Patient-derived tumor models

Patient-derived xenograft (PDX) models are important tools in oncology research, accurately reflecting tumor heterogeneity while faithfully recapitulating the features of its TME. Maintaining and propagating PDXs on the CAM using the standard methodology is straightforward (s. 'General experimental approach'), with high tumor take rates across diverse cancer types [66, 113]. In fact, Charbonneau and colleagues showed that engraftment rates of > 95% could be achieved for glial tumors in the CAM model, whereas only 39–69% were reported in murine xenografts [113]. CAM-derived xenografts closely resemble the original tumors, preserving key histological features and intratumoral heterogeneity [37, 113]. The CAM provides rapid vascularization of the grafts, which enables the formation of micrometastases and local invasion – features that correlate with the original tumor's aggressiveness [37]. Indeed, the CAM model has even been used to generate PDXs from circulating tumor cells (CTCs), including circulating cancer stem cells (cCSCs), while forming tumors that retain phenotypic and molecular features of the primary malignancy [114–116]. This approach provides insights into metastatic potential and supports drug testing in a rapid assay, representing a valuable tool for individualized therapy approaches [114–117].

The low turnaround time is especially relevant for the application in personalized medicine, where drug efficacy and treatment response can be screened to optimize therapy [113, 117]. Consequently, Barnabas and colleagues utilized chick PDXs for proteomic screening and drug testing, thereby optimizing the treatment strategy for a patient with progressive disease [117].

Thus, the CAM-PDX model is increasingly recognized as a practical complement to murine xenografts and *in vitro* long-term patient-derived cultures, particularly for personalized oncology applications requiring time-efficient, biologically relevant tumor modeling.

Advantages and limitations

The CAM model offers several key advantages compared to other cancer models: (a) Its natural immunodeficiency allows xenografting of human tumor cells without immune rejection; (b) Tumors develop within 5–10 days, enabling rapid and medium-throughput functional and drug screening; (c) It supports histologically and molecularly representative tumors, preserving stromal and vascular components; (d) Its dense vasculature facilitates real-time imaging of tumor angiogenesis, metastasis, and cell behavior; (e) Its immediate optical accessibility facilitates longitudinal imaging studies (f) It accommodates a wide range of tumor sample types, including cell lines, patient-derived xenografts (PDXs), and circulating tumor cells (CTCs); (g) It requires a relatively low initial

investment in infrastructure, as egg incubators are often inexpensive; (h) The involvement of ethical committees is normally not required; and (i) Topical and systemic drug administration is straightforward. Overall, this general accessibility makes it well-suited for early-phase *in vivo* testing, particularly in settings with limited resources, or for the time-sensitive personalized medicine.

Nonetheless, several limitations must be considered: (a) The short experimental window prevents assessment of long-term features such as tumor remission, recurrence, or chronic drug effects; (b) Oral administration of drugs or pre-drugs is not feasible, and compounds must be solubilized for injection, posing challenges for poorly soluble agents; (c) As in any whole-organism model, systemic dosing is constrained by tolerability and embryo viability, which enforces physiologically relevant exposures but may limit escalation for poorly tolerated compounds or solvent systems; (d) Even though *in vivo* imaging is possible, 3D imaging of tumor growth is limited by the egg-shell opacity; (e) Environmental factors—such as oxygen tension, pH, temperature, and humidity—should be carefully controlled to prevent confounding effects; and (f) Similar to other animal models, inter-species immunological and/or metabolic variability may limit the translational potential of individual results.

In sum, the CAM model is best used for short-term, cost-effective, medium-throughput *in vivo* studies focused on tumor engraftment, angiogenesis, metastasis, or drug efficacy. It is a powerful screening tool that bridges the gap between *in vitro* experiments and murine models. However, its biological and methodological constraints necessitate concise follow-up studies in mammals to ensure translational reliability.

Zebrafish (*Danio rerio*)

General experimental approach and alternative setups

Growing out of the pioneering work of George Streisinger and colleagues beginning in the 1980s [118, 119], zebrafish became widely adopted as an experimental model organism with the publication of the first large-scale genetic screens in 1996 [31, 120]. From this early work, the advantages of the zebrafish system—including powerful genetics, large clutch size, and rapid development of transparent embryos external to the mother—were already evident.

Since a pair of zebrafish can produce several hundred fertilized embryos from a single mating, and nucleic acids or proteins can easily be injected into embryos at the single-cell stage, they are amenable to high-throughput genetical modeling. Of note, a zebrafish ortholog is known for 70% of human genes (85% of disease-related genes [121]), and the organ structure and physiology of fish is similar to other vertebrates, including hematopoiesis, liver synthetic and metabolic function, vascular and

lymphatic systems and both innate and adaptive immunity [122–124]. Early genetically-engineered zebrafish models of T-cell leukemia [125] and melanoma [126] established the utility of the zebrafish model for building animal models that recapitulated key features of human cancers. Further development of technologies such as transposon-based transgenesis and mutagenesis [127, 128] and implementation of conditional gene expression strategies [129–131] enabled rapid expansion of the spectrum of cancers for which models were available, including neuroblastoma [132], sarcomas [133–136], hepatocellular cancer [137], brain tumors [138, 139] and others [29, 140]. These models have been leveraged for functional genomics [141, 142] and for insight into the cell lineage of origin of cancers [141, 143]. Hence, in a typical experiment, a tumor model is generated by mosaic, conditional, and/or tissue-specific expression of an oncogene or loss of a tumor suppressor [144].

Zebrafish are sensitive to carcinogens and can develop a wide range of malignancies [145, 146]. Consequently, methods have been developed to expose fish to carcinogens as well as antineoplastics, small molecules, cellular therapies, radiation, and other therapies (s. ‘Therapy modalities’).

In addition to genetic models, another major use of zebrafish is as a platform for xenograft studies. Pioneering work by Nicoli and Presta demonstrated that human tumor cells implanted into zebrafish embryos could stimulate neovascularization from host vessels and that anti-angiogenic agents could suppress this response [147]. Zebrafish embryos rapidly develop a functional vascular and lymphatic circulatory system over the first few days of life [148–150] and the transparent embryos and larvae support high-content imaging [28, 151, 152]. Transgenic zebrafish embryos expressing fluorescent reporters in vasculature also facilitate studies of tumor-related angiogenesis and the effects of anti-angiogenic therapies [153–156]. Leveraging immunodeficient zebrafish strains, xenograft experiments can also be performed in adult fish [157]. Mutagenized strains that lack pigmentation even at adult stages are also available [158]. Subsequently, the xenograft model has been adopted for a wide range of studies of cell- and patient-derived xenografts (s. ‘Patient-derived tumor models’).

Analysis and experiment readouts

One of the big advantages of the zebrafish system is the optical transparency of embryonic and larval zebrafish, which allows detection and tracking of fluorescently labeled tumor cells. Fluorescent proteins such as eGFP can be incorporated into tumor models and xenografts, which facilitates high-resolution imaging at the single-cell level.

If a fluorescent label is incorporated into the transgenic construct, the area, volume, and intensity of tumor-specific fluorescence can be measured in multiple biological replicates to generate statistics for tumor growth rates, metastatic spread, and response to therapies (Fig. 2A, C). Live imaging allows serial measurements over time, beginning at the earliest stages of embryonic development, which can be complemented by endpoint assays on fixed tissue (either whole-mount preparations of embryos/larvae, or sections of adult fish tissue) including markers of cell proliferation, cell death, DNA damage, signaling pathway activity and others [159].

Histopathologic examination can be performed on cryosections or on sections of formalin-fixed, paraffin-embedded (FFPE) tissues, including hematoxylin & eosin (H&E) stains (Fig. 2D) and immunohistochemistry (Fig. 2E). A frequent limitation to immunostains of zebrafish cancer models is the lack of cross-reacting antibodies for specific zebrafish antigens. In situ hybridization to delineate expression of an mRNA of interest can provide a useful substitute. As with mammalian tissues, zebrafish tumors and surrounding non-tumor tissue can be subject to spatial transcriptomic techniques and multiplex immunofluorescence to generate a more detailed portrait of the tumor in its host environment [160].

Measurement of tumor growth can be performed by serial imaging using light microscopy, especially useful for pigmented superficial tumors such as melanomas. Alternative imaging modalities that have been applied include bioluminescence imaging, ultrasound, computed tomography, and magnetic resonance imaging [161–164]. Most frequently, incorporation of a fluorescent marker into the transgenic construct allows for live imaging by epifluorescence microscopy. The tumor mass can be quantified based on the area and/or intensity of the fluorescent signal. Fluorescence microscopy is also a mainstay in evaluating the fate of cells xenografted into larvae, most straightforwardly for measurement of tumor response to therapies [165]. The xenograft model also allows detection of cell spread outside the primary tumor as a measure of metastatic potential (Fig. 2B).

Therapy modalities

As mentioned above, several routes are available for administration of therapies to zebrafish. Intraperitoneal injections can be easily performed in adult animals, and intravenous injection, widely available for rodent and larger animal models, is also possible in zebrafish. At the larval stage, capillary micropipettes can be used to inject small volumes into the duct of Cuvier, which drains venous blood into the sinus venosus of the heart. At the adult stage, intravascular access can be achieved via intracardiac, retroorbital, or intravenous injection [166]. Oral administration of drugs can occur via gavage




Fig. 2 Overview of *D. rerio* zebrafish model. **A.** Generation of genetically engineered tumor models. Single cell-stage embryos are injected with DNA, RNA and/or protein to activate or repress cancer-related genes of interest. Inclusion of a fluorescent marker allows monitoring of the effects of genetic manipulations during early embryonic and larval stages. Over weeks to months, animals may develop tumors which can be further analyzed. **B.** Zebrafish xenograft system. Fluorescently labeled human cancer cells are implanted into larval stage zebrafish. Cells are implanted into the hindbrain ventricle (HB), the ventral perivascular space (PVS), or via intravascular injection into the Duct of Cuvier (DoC). Xenografted embryos can be exposed to drugs such as small molecules to measure antitumor effects. Alternatively, the spread of tumor cells to distant sites can be used as a measure of metastatic potential. **C-E.** Analysis of tumor histology. **C.** 3-month-old zebrafish with mosaic expression of the human EWSR1::FLI1 fusion oncogene. Green fluorescence (white rectangle) marks tumor site. **D.** H&E stain of muscle-infiltrating tumor showing small round blue cell histology consistent with Ewing sarcoma. **E.** Immunohistochemical detection of CD99, a clinical marker of Ewing sarcoma. **F.** Xenograft of GFP-labeled human CHLA9 Ewing sarcoma cells into kdrl: DsRed transgenic zebrafish larva. Magenta color marks vasculature. T: primary tumor implantation site. Arrows: metastatic cells. **G.** Confocal microscope imaging of CHLA9 cells extravasated into the space between the dorsal aorta (DA) and posterior cardinal vein (PCV). Scale bar: 50 microns. A and B created in BioRender (<https://BioRender.com>). C-E derived from Vasileva et al. eLife 2022. F and G courtesy of Ingrid Leck, PhD

into both larval and juvenile/adult fish or by incorporation of drugs into food [167–169]. Uniquely for aquatic organisms such as fish and frogs, drugs can be administered via waterborne exposure by simply adding compounds to the water. In the immersion approach, uptake

occurs via a combination of absorption through the skin, gills, and by the animals swallowing drug-containing water. Though technically simple and especially useful for high-throughput screens performed on embryos [170,

[171], poor solubility of drugs can impair the efficiency of aqueous administration.

Radiotherapy has also been successfully modeled in zebrafish, with studies showing tissue-specific and systemic effects of fractionated or single-dose irradiation in both larvae and adult fish [161, 172–174]. Zebrafish display dose-dependent DNA damage, cell death, and regeneration responses in tumor-bearing tissue, allowing the investigation of radiosensitizers or radioprotective agents [173].

Targeted therapies and biologics, including monoclonal antibodies, extracellular vesicles, lipid nanoparticles, and engineered immune cells (e.g., CAR-T cells), have been applied in zebrafish. These are typically administered via injection into embryos or adult fish and tracked via fluorescence or functional assays [175–178]. Studies evaluating the potential of immune checkpoint blockade experiments in zebrafish are ongoing [179].

Pharmacodynamic and pharmacokinetic (PD/PK) limitations persist, particularly regarding compound metabolism and clearance, as these are less well-characterized compared to rodent systems [171, 180]. However, the ease of serial imaging and biomarker quantification may act as surrogate parameters, which could partially compensate for these limitations, particularly in short-term efficacy studies.

Overall, zebrafish offer a scalable and versatile *in vivo* platform for evaluating drug efficacy, toxicity, mechanism of action, and delivery strategies—especially in the early stages of anti-cancer drug development.

Patient-derived tumor models

One of the most rapidly growing uses of the zebrafish system is adaptation of the larval xenograft model for personalized medicine approaches, including studies aimed at predicting an individual tumor's sensitivity to specific therapies or propensity for metastasis [181–183]. These zebrafish PDX (zPDX) models highlight the potential of fish to serve as a patient-specific avatar. A 3-day-old zebrafish has largely completed organogenesis and exhibits well-established vascular, lymphatic, and innate immune systems. Adaptive immunity is not present until the thymus develops at around 7–10 days of life. Thus, patient-derived tumor cells can be xenografted without the need for immunosuppression. Typical sites of implantation include the perivitelline space, the hindbrain ventricle, or directly into the circulation [165] (Fig. 2B).

Several zPDX approaches have been described, and the field lacks consensus on a single, gold-standard technique. To minimize phenotypic drift of patient-derived tumor cells and to avoid artifacts of *in vitro* culture, many zPDX studies rely on the use of lipophilic dyes to label human tumor cells. While dye labeling facilitates rapid labeling and visualization of the implantation, the

dye may persist in dead cells or debris or be taken up by macrophages, potentially creating a false-positive signal. As an alternative, labeling of PDX cells with fluorescent reporter proteins or use of functional readouts (e.g., cell proliferation or cleaved Caspase 3) may be more reliable. On average, a maximum of several hundred tumor cells are implanted, which may limit the ability of a zPDX to truly represent intratumoral heterogeneity or to fully assess the impact of non-tumor cells such as macrophages and cancer-associated fibroblasts (though adult immunocompromised hosts can accommodate much larger numbers of cells [184]).

Despite these limitations, numerous studies have documented the utility and predictive power of the zPDX system. zPDX avatars have been used to test patient tumor-specific effects of radiation [174], chemotherapy, and small molecules [182, 185–188], to investigate effects of innate immune evasion [189], and to predict tumor metastatic propensity [190, 191]. zAvatars have been demonstrated to predict risk of progression in primary colorectal cancers [192], and a recent study of high-risk breast cancer compared results of the same therapy in patients and in matching zAvatars, finding 100% concordance between the zebrafish results and the patient's clinical response [193]. The success of these approaches has prompted the design of a randomized clinical trial testing the utility of selecting treatment regimens based on the zAvatar assay [194].

Advantages and limitations

The zebrafish system offers several notable advantages in cancer modeling: (a) Its optical transparency, especially in embryonic and larval stages, enables high-resolution, real-time imaging of tumor initiation, progression, and metastasis; (b) The high genetic and physiological overlap with humans enhances the translational value; (c) Genetic manipulation is rapid and cost-effective, allowing creation of transgenic models and CRISPR-based gene editing; (d) It supports both genetically engineered models and xenograft approaches, including patient-derived xenografts (zPDX), in early-stage natural or genetically induced immunoincompetence; (e) High fecundity and small size facilitate high-throughput drug and genetic screening at scale; (f) Diverse routes of drug administration are feasible (e.g., immersion, injection, oral), enabling flexible pharmacological studies; (g) Zebrafish models increasingly support personalized medicine pipelines by predicting patient-specific therapy responses; (h) As early-stage larvae are not legally classified as animals in many jurisdictions, the model allows for rapid and uncomplicated study initiation.

Despite its advantages, the zebrafish model has several limitations: (a) Adult zebrafish are pigmented unless using specific mutant strains, reducing imaging quality

compared to embryos; (b) Tumor xenografts typically involve small cell numbers, which may limit the modeling of intratumoral heterogeneity and TME interactions; (c) Cross-species differences in signaling ligands, chemokines, and immune interactions may reduce translational fidelity; (d) The optimal temperature for zebrafish (28.5 °C) differs from the 37 °C optimal for mammals; thus, xenografting of human cells is typically performed at a compromise temperature of 32–34 °C; (e) Zebrafish lack certain mammalian organs (e.g., mammary glands), limiting modeling of some human cancers; (f) Limited data on zebrafish-specific pharmacokinetics (ADME/PK-PD) may necessitate follow-up validation in rodent models; (g) While adaptable for therapy testing, immunotherapy studies remain constrained due to immature immune system in larvae and species-specific immune barriers (though the development of a humanized model offers more possibilities to study hematopoietic cancers [195]); and (h) As adult zebrafish are often subject to animal protection laws, maintaining a zebrafish colony may be less cost-efficient and require additional approvals.

Fruit fly (*Drosophila melanogaster*)

General experimental approach and alternative setups

Drosophila melanogaster has served as a central model organism in developmental biology and cancer genetics for over a century. It offers a genetically tractable and cost-effective platform to study tumorigenesis at the organismal scale. As a non-vertebrate model, *Drosophila* aligns with the 3R principle—particularly Replacement and Reduction—while enabling detailed mechanistic studies of cancer biology [196, 197]. This includes the first links between phenotypes and genes and chromosomes in the famous Fly Room of Thomas Hunt Morgan [198] and the discovery of cancer-related pathways such as Hedgehog [24], Hippo [199], Notch [200], Wnt/wg [201], EGFR/Ras/MAPK, JAK/STAT, and PI3K/Akt/mTOR [202].

Experimental protocols typically begin with genetic crosses to combine tissue-specific drivers and oncogenic or RNAi constructs. Within days of adult emergence, flies develop visible tumor phenotypes—ranging from tissue hypertrophy to disseminated growth [203, 204]. These can be assessed macroscopically (e.g., bloating, reduced motility, lethality) or microscopically using fluorescent reporters and immunostaining. Environmental factors such as hypoxia, oxidative stress, hyperthermia, or dietary restriction can be modulated to study context-dependent tumor behavior [203].

The fly's genetic toolkit enables the study of tumor initiation, progression, and therapy response [205], leveraging RNAi lines, CRISPR-Cas9, guideRNAs, and inducible transgene systems. These resources have allowed the modeling of diverse cancers, including colorectal, breast,

glial, and hematologic malignancies (reviewed in [27, 203, 205–212]). In addition, spatial and temporal gene control permits the induction of tumors closely mimicking human cancers [203, 213, 214]. Indeed, tumor modeling in *Drosophila* typically relies on the binary GAL4/UAS expression system, which allows combined spatio-temporal control of (onco-)gene expression (e.g., RasV12) or tumor suppressor gene knockdown (e.g., p53, PTEN, APC) [215, 216] in specific tissues [217–219]. Here, intestinal stem cells (ISCs), neural precursors, imaginal discs, and hemocytes are commonly targeted [213, 220], while the Flippase/Flippase Recognition Target (FLP/FRT) or Mosaic Analysis with a Repressible Cell Marker (MARCM) systems enable clonal analysis of tumor growth and cell competition in a lineage-specific manner [221, 222].

Upon gene expression induction, flies develop neoplastic growth in epithelial or neural tissues. These tumor masses can even be serially transplanted into host flies to investigate invasion and metastasis [223, 224]. Recent advances further allow dissection of microenvironmental and inter-organ interactions, e.g., using dual expression systems (e.g., LexA/LexAop in parallel with GAL4/UAS) to manipulate tumor and stromal compartments independently [225, 226].

The short generation time (~ 10 days), low maintenance cost, and robust genetic tools make *Drosophila* uniquely suited for large-scale cancer biology experiments and mechanistic dissection of tumorigenic processes [196, 197].

Analysis and experiment readouts

The *Drosophila* model offers countless methods to assess consequences of genetic mutations, but also studies of diet, age, irradiation, hypoxia, hyperthermia, oxidative stress, immune rejection, TME *et cetera* are possible as well as their use in combination (e.g., irradiation plus genetic/drug inhibition). The tractable anatomy and short lifespan of *Drosophila* facilitate high-throughput phenotyping and detailed analysis of tumorigenesis [227]. Tumor development can be macroscopically scored (e.g., abdominal distension, lethality) or microscopically evaluated via fluorescent reporters [228–230]. Tumor growth, proliferation, apoptosis, and differentiation are quantifiable using immunohistochemistry, reporter lines (e.g., Notch-, Wnt-, MAPK-activity sensors), and cell-type-specific markers [214, 231–233]. Invasion and metastasis studies leverage tracking of disseminating cells via fluorescent lineage markers [223, 224].

Fluorescently labeled transgenes under tissue-specific drivers allow *in vivo* imaging of tumor formation, clonal expansion, and disseminations [217]. Tumor cell proliferation can be tracked by phospho-histone H3 staining, while apoptosis is assessed using cleaved Caspase-3 or

TUNEL assays [234]. Tissue architecture and differentiation states are further analyzed by immunohistochemistry for epithelial or lineage-specific markers [235].

Clonal and lineage-tracing tools such as MARCM [222], Flp-out [236], and ReDDM [237–239] can be used to address the effects of intrinsic and extrinsic factors on tumor behavior with spatiotemporal control of the onset of tracing and genetic manipulation [240]. Observations such as changes in cell fate in tumors of flies [241] complement and add functional knowledge to the worsened survival of patients with, e.g., CRC with a high percentage of enteroendocrine cells [242].

Functional readouts of signaling pathway activity are routinely performed using genetically encoded reporters. For example, Notch [243], Wnt/Wingless [244], Ras/MAPK [245, 246], and Jak/Stat [236] activity can be tracked using fluorescent transcriptional sensors, allowing quantitative assessment of pathway dynamics before and after tumor initiation or therapeutic intervention [247–249].

In recent years, *Drosophila* cancer models have been used to investigate tumor cell dissemination from primary tumours [250–252] involving processes and/or factors stimulating EMT in flies [237, 238]. Emerging methods such as FACS allow isolation of circulating tumor-like cells from whole-fly homogenates for downstream transcriptomic or proteomic analyses [73, 250, 251, 253]. Combined with transplantation assays, this supports the assessment of tumor invasiveness and metastatic potential *in vivo* [254, 255]. Consequently, new genetic approaches taking advantage of dual expression systems can be employed to assess and manipulate TME effects and organotropism *in vivo* [246, 256]. Together, these sophisticated methods allow in-depth investigation of early metastatic events with single-cell resolution and drug screens aiming to identify molecules inhibiting metastasis.

Therapy modalities

Drosophila offers a versatile and high-throughput system for *in vivo* testing of anticancer therapies. Compounds are most commonly administered by blending them into fly food, ensuring systemic exposure with minimal technical effort and allowing for scalable screening [227, 257, 258]. Alternative application routes such as topical delivery and microinjection are also possible, yet are used less frequently due to throughput and practicality considerations [259].

Thanks to an almost 80% conservation of disease- and cancer-causing genes, drugs developed for human application often work in flies [202]. Studies from the Cagan lab set the cornerstone for more complex drug screening approaches, including repurposing of FDA-approved drugs not currently used in cancer therapy [260].

Therapeutic efficacy is assessed by measuring changes in survival rates, tumor burden, or molecular pathway activity. Researchers employ tissue-specific fluorescent reporters and immunostaining to visualize and quantify tumor growth and regression [251, 258]. Targeted inhibitors of conserved cancer pathways—such as MEK, PI3K, and mTOR—have shown efficacy in *Drosophila* models with oncogenic alterations present in many human tumors [217, 259, 261]. Quantitative imaging and the use of genetic pathway sensors (for example, for Notch, Ras/MAPK, or Wnt signaling) enable real-time monitoring of the effects of various treatments [251, 262].

Radiotherapy, while not a routine modality in *Drosophila* studies, can still be modeled using low-dose ionizing irradiation to explore DNA damage responses and mechanisms of radiosensitization [263–265]. However, *Drosophila* does not allow for the precise, clinically relevant application typical in mammalian models.

Due to the absence of adaptive immunity in flies, direct modeling of immunotherapies is not possible [266]. Nevertheless, interactions between tumors, stromal cells, and the innate immune system can be experimentally interrogated and provide insight into TME dynamics [267–270].

In summary, *Drosophila melanogaster* is highly suitable for early-phase screening of anticancer drugs and combination therapies. While not fully compatible with every clinical modality, this system offers a highly upscaleable, rapid, cost-effective, and ethically favorable platform for the *in vivo* assessment of therapeutic efficacy in genetically defined tumor models [227, 258, 261] (Fig. 3B).

Patient-derived tumor models

An alternative to xenotransplantation performed in larger animals, *Drosophila* genetics allow the simulation of patient-specific cancer genotypes through the generation of “fly avatars.” These avatars are produced by introducing combinations of oncogenic mutations—identified from patient tumor sequencing—into specific tissues of the fly [205, 262, 271]. This system enables high-throughput drug screening, wherein disease-modeling flies are crossed with RNAi or CRISPR libraries and treated with candidate compounds delivered through food or topical application. Quantifiable phenotypic readouts—such as tumor size, signaling pathway activation, or organismal survival—allow for the rapid identification of effective, genotype-matched drug responses [272–274]. A first demonstration that drugs identified in flies can translate into clinical treatment of medullary thyroid carcinoma [275] paved the way for directed development of precise genetically complex fly models.

Technological advances have further refined this pipeline. Bangi et al. (2016) introduced multiplexed short-hairpin RNAi (shRNAi) arrays and semi-automated robotic screening, significantly accelerating




A General experimental procedure - Patient tumor sequencing and generation of personalized Fly Avatars**B Alternative experimental procedures****C Analysis and data processing**

Fig. 3 Overview of *Drosophila* model. **A.** Generation of personalized fly avatars after sequencing of tumor samples. CRC: colorectal cancer. **B.** Schematic representation showing a timeline for screening of drugs and efficacy assessment using fly avatars, starting with the induction of intestinal tumors in adult flies and proceeding with tumor growth, organ-specific metastasis, and finally tumor-elicited lethality. **C.** Analysis and data processing. Left: Analysis of tumor growth on cellular level by microscopic imaging of tumor-bearing intestines with fluorescent labeling of intestinal stem cells. Center: Assessment of migration and metastases of fluorescently labeled and traced tumor cells. Right: Drug screening to rescue avatar survival by high-throughput assays testing single drugs and drug combinations printed on microwell plates and CRC avatar flies. Effective drugs will be identified by their ability to prolong the survival of avatar flies and are further tested by their impact on tumor growth and metastasis formation in the other analyses. The combined results will contribute to recommendations for the tumor board. Created in BioRender (<https://BioRender.com>)

the timeline of avatar creation and drug testing—an essential improvement for late-stage cancer patients [262]. Combining this approach with CRISPR-Cas9 technology, Zipper et al. (2022) developed a protocol involving scarless restriction enzyme strategies for multiplexed guide RNA array generation. This method improves editing efficiency, mitigates genetic compensation mechanisms, and reduces development time for complex avatars [276] (Fig. 3A).

Taken together, *Drosophila* avatars constitute a rapid, cost-efficient, and 3R-compliant platform for modeling complex patient-specific mutational landscapes and guiding targeted therapeutic development at scale.

Advantages and limitations

The *Drosophila melanogaster* system offers several unique advantages for cancer modeling and drug discovery: (a) A powerful and flexible genetic toolkit—including GAL4/UAS, FLP/FRT, MARCM, RNAi, CRISPR, and dual expression systems—enables precise spatial and temporal control of gene expression and modeling of complex mutational landscapes; (b) Rapid generation time (~10 days) and low maintenance expenses allow for high-throughput, statistically robust screening with large biological replicates; (c) Fluorescent reporters and genetically encoded pathway sensors (e.g., for Notch, Wnt, Ras/MAPK, JAK/STAT) enable live tracking of tumor growth, clonal behavior, and therapy response at cellular resolution; (d) Fly avatars—genetically engineered to recapitulate patient-specific mutations—support personalized drug screening using multiplex RNAi/CRISPR approaches and semi-automated readouts; (e) Serial transplantation of fly tumors enables assessment of tumor cell propagation, invasiveness, and metastatic behavior *in vivo*; (f) Genetic and environmental manipulation targeting tumor or normal tissue enable investigation of inter-organ signaling and systemic effects such as cachexia; (g) Despite lacking an adaptive immune system, innate immunity and tumor-stromal interactions are accessible for mechanistic studies, (h) Maintenance of fly models requires minimal infrastructure and is generally inexpensive.

Nonetheless, several limitations must be considered: (a) As a non-vertebrate, *Drosophila* lacks certain anatomical structures (e.g., vasculature, bone marrow, lungs) and physiological systems (e.g., adaptive immunity), limiting its utility for modeling particular organ-specific pathologies, interaction of tumor cells and vasculature, and immunotherapies; (b) Drug pharmacokinetics and metabolism differ from humans; (c) Radiotherapy is only feasible using low-dose, non-targeted irradiation; (d) While fly avatars model mutational complexity well, they do not include patient-derived cells or native human TME; (e) Tumor histology and tissue architecture in flies

differ from mammals, which may limit modeling of some tumor types or stromal interactions; (f) The small body size restricts longitudinal monitoring of systemic disease processes like tumor-induced immunosuppression; (g) Some conserved signaling pathways show context-dependent functional divergence, requiring cautious extrapolation to human biology.

In summary, *Drosophila* represents a fast, cost-effective, and ethically favorable *in vivo* model for genetic dissection of tumorigenesis and early-phase drug screening (Fig. 3C). While it lacks several mammalian features essential for translational cancer research, its unparalleled genetic tractability and screening capacity make it a powerful component in the preclinical modeling pipeline. Undoubtedly, the future of cancer research in the fly is bright: Might it be the arrival of prime editing allowing oncogenic transformation *in vivo* [277] or CAR-M (RaceCAR macrophages) cancer immunotherapy [270], the integration of newest discoveries into well-described model organisms will continue to revolutionize the field of 3R-compliant cancer modeling.

Caenorhabditis elegans

General experimental approach and alternative setups

The nematode *C. elegans* is a metazoan model organism first introduced by Sydney Brenner as a platform to study developmental biology and cellular processes *in vivo* [233, 278]. Its invariant and deterministic cell fates allow the tracking of each individual somatic cell during embryogenesis and larval development, from their origin until their physiological selective elimination [279, 280]. Notably, cell death defective (*ced*) *C. elegans* mutants enabled the discovery of programmed cell death as a genetically regulated phenomenon [281]. Indeed, Horvitz and colleagues identified the genes CED-3, CED-4, and CED-9 as core components of apoptosis, which later revealed functional homology to the mammalian caspase cascade and BCL2 pathway—establishing apoptosis as a conserved tumor suppressor mechanism [281, 282].

While the nematode doesn't develop cancer largely due to the early developmental terminal differentiation of the somatic cells, that in the adult are devoid of any cell division potential, the germline can develop tumors, providing a dynamic model for genome stability, DNA damage response (DDR), and oncogenic signaling [283, 284]. Upon DNA damage, the *C. elegans* p53-like CEP-1 protein induces pro-apoptotic factors EGL-1 and CED-13, which inactivate CED-9 to trigger cell death (Fig. 4A) [285, 286]. As p53 is the single most frequently mutated gene in human cancers [287], the availability of a homolog in a powerful genetic system enabled the discovery of novel regulatory mechanisms. Based on discoveries in the nematode model, conserved layers of p53 regulation were uncovered, including translational repression




Fig. 4 Overview of *C. elegans* model. **A**. In the late meiotic pachytene zone, apoptotic corpses are formed that can be visualized in differential interference contrast (DIC) microscopy and stained with Acridine Orange (AO). **B**. DNA damage in late meiotic pachytene cells triggers highly conserved DNA damage checkpoint signaling that activates the tumor suppressor CEP-1/p53, which transcriptionally induces the BH3-only domain proteins EGL-1 and CED-13. These PUMA and NOXA homologs inactivate the BCL-2 homolog CED-9, which then releases CED-4 to trigger the activation of the caspase CED-3, thus executing apoptosis. **C**. The proto-oncogenic RAS signaling pathway regulates cell divisions during the development of the vulva, and hyper-activation leads to extra cell division rounds, resulting in the formation of multiple vulvas. **D**. A wide range of methodologies allows the *in vivo* analysis of the consequences of mutations in conserved tumor suppressors or oncogenes in distinct tissue types, developmental stages, and aging. Transgenes can be expressed with fluorescent markers or other tags, mutations can be generated by gene editing or mutagenesis, and genes can also be knocked down by RNAi. The effects of small molecules such as chemotherapeutic drugs can be assessed upon feeding the animals on plates supplemented with such molecules or exposing them in liquid culture to drugs. A generated by Dr. Christina Efraimoglou, B-D created in BioRender (<https://BioRender.com>)

by GLD-1 and protein turnover via SCF and CYLD complexes [288–293].

Conserved oncogenic signaling pathways can be interrogated in *C. elegans* using genetically tractable models with well-defined phenotypic outputs. For example, mutations in RAS/MAPK pathway genes such as *let-60* (RAS homolog) and *mpk-1* (ERK/MAPK) result in a multivulva phenotype, providing a direct and quantifiable readout of RAS/MAPK pathway activation *in vivo* (Fig. 4B) [294–296]. Similarly, loss-of-function mutations in *gld-1*, a translational repressor required for meiotic entry, induce germline tumors due to mitotic re-entry of undifferentiated cells [297, 298]. These models facilitate the functional analysis of oncogene activation, cell fate disruption, and proliferative transformation in a genetically

defined system. Modern genetic tools—including chemical mutagenesis, RNAi knockdown, and CRISPR/Cas9 genome editing—enable the generation of loss- or gain-of-function alleles, reporter strains, and targeted knock-ins (Fig. 4C) [299–301].

Gene mutations can either be introduced stochastically or through targeted approaches. Historically, chemical mutagenesis, for instance, through N-ethyl-N-nitrosourea (ENU) exposure, has been used to generate strains carrying mutant alleles, which are then phenotypically characterized and the underlying mutation identified. Since the advent of whole genome sequencing (WGS) approaches, the identification of mutant alleles has been greatly improved [302]. A major step towards studying gene function was the implementation of RNA

interference approaches that could in principle allow knocking down any of the roughly 20,000 nematode genes [303, 304]. In recent years, CRISPR/Cas9 gene editing methods were also advanced in *C. elegans* and are routinely applied to generate mutant alleles, including loss-of-function and gain-of-function alleles, as well as knock-in constructs ranging from engineered promoters to various types of tags [305]. Notably, *C. elegans* has recently been applied in a translational setting as a functional diagnostic tool, where chemotaxis-based N-NOSE testing enabled prediction of chemotherapy response in esophageal cancer patients, underscoring its potential utility in treatment stratification [306].

Together, these features establish *C. elegans* as a powerful, 3R-compliant model for dissecting conserved cancer-related mechanisms such as apoptosis, DNA damage signaling, and oncogenic transformation at single-cell resolution in a whole-organism context.

Analysis and experiment readouts

C. elegans provides a powerful and genetically accessible platform for *in vivo* analysis of cancer-relevant processes such as apoptosis, DNA damage response, and oncogenic signaling (Fig. 4). Its optical transparency and invariant cell lineage facilitate dynamic tracking of molecular and cellular changes across development and under stress conditions.

Fluorescent reporters, introduced through germline microinjection, allow dynamic tracking of gene expression and protein localization in live animals [307]. These constructs can report transcriptional states, monitor subcellular protein distribution, or pathway activation in response to physiological or genotoxic stimuli [308]. The optical transparency of *C. elegans* supports real-time visualization of cellular processes such as mitosis, protein dynamics, and apoptosis [280, 309]. Apoptotic events can be identified via their characteristic refractile morphology under DIC microscopy or using fluorescent markers such as CED-1::GFP or Acridine Orange staining [283, 310, 311]. Developmental apoptosis is commonly quantified by scoring persistent ‘undead’ cells in *ced* mutants [282, 312], while DNA damage-induced germline apoptosis serves as a robust functional readout of DNA damage response (DDR) gene activity [284, 289]. For instance, defects in global-genome nucleotide excision repair (GG-NER) that in humans lead to exquisite hypersensitivity of UV-induced skin cancer lead to genome instability in germ cells of *C. elegans* [313–315].

Assays involving exposure to genotoxic agents like ionizing radiation (IR) or ultraviolet (UV) light are commonly used to assess genome integrity. IR mainly affects proliferating germ cells and early embryos, while UV exposure induces DNA damage and growth arrest in somatic tissues [316, 317]. These assays facilitate the

dissection of conserved DNA repair pathways and allow functional interrogation of genome maintenance mechanisms [285, 318].

Oncogenic signaling can be monitored using genetically defined phenotypic outputs. As mentioned above, constitutive RAS/MAPK activation results in a multi-vulva phenotype that provides a direct and quantifiable endpoint [294]. In the germline, aberrant ERK signaling disrupts oocyte differentiation, and loss of *gld-1* leads to tumor-like mitotic overproliferation [297, 319]. These phenotypes serve as reliable indicators of disrupted differentiation and proliferative transformation.

Altogether, these analytical tools make *C. elegans* a highly informative and scalable model for functional studies of cancer-relevant genes, processes, and pathways *in vivo*.

Therapy modalities

C. elegans can not only be used to obtain insights into basic cancer biology, but it could also aid in better understanding therapeutic targets, modes of action, and side effects of both novel and established pharmaceuticals. Drugs, including chemotherapeutics, can be easily administered to *C. elegans* by incorporating the compounds into the nematode’s growth environment through agar plate supplementation, where for instance common chemotherapeutics such as cisplatin and doxorubicin have been assayed [320, 321]. In addition, drugs may be administered via bacterial diet incorporation, where they are added to the bacterial feeding source prior to seeding the agar plates. An advantage of this approach is the possibility to study the contribution of the bacteria’s metabolism to the preprocessing of certain drugs, which can shed light on the effect of the human bacterial microbiota on cancer drug efficacy—an emerging concern in human cancer therapy [322]. Either of these methods provides a straightforward, reproducible, and scalable drug administration system for *C. elegans*.

In terms of drug discovery, the ease to produce large populations of worms simplifies the implementation of high-throughput approaches to screen small-molecule libraries [323]. Provided that drugs may be absorbed directly through the nematode’s cuticles, it is worth noting that several *C. elegans* strains carrying mutations affecting cuticle integrity have been reported to have increased drug absorption [324]. Using these strains with increased cuticle permeability in drug screens may reduce potential false-negative hits due to insufficient doses reaching the target cells. Overall, the use of *C. elegans* in the context of drug testing presents clear advantages in terms of cost, data robustness, and low amounts of required chemicals, which may facilitate the testing at early stages of compound development.

Advantages and limitations

C. elegans has facilitated the discovery of biological phenomena, as evidenced by the multitude of Nobel Prizes awarded to worm researchers. Taken together, *C. elegans* has provided important mechanistic insight into the function of processes that are causally linked to cancer development while providing distinct advantages: (a) It provides a simple animal model with distinct cell and tissue types; (b) The life cycle is short, and within three days after birth the reproductive age is reached and each hermaphrodite can produce 300 offspring in a matter of days; (c) Over 70% of the cancer-related genes and pathways are highly conserved and can be studied in the worm [325]; (d) Even highly complex biological phenomena such as the organism wide systemic responses to genome instability have been identified in this system; (e) Inheritable consequences of DNA damage such as the formation of de novo structural variants can be followed through generations and the relative contribution of DNA repair and epigenetic mechanisms can be investigated; and (f) It provides a suitable platform not only for genetic screening but also for *in vivo* functional investigation of mechanisms in development, adulthood and aging.

Conversely, the simplicity and evolutionary distance of *C. elegans* pose limitations on studying complex human diseases such as cancer. While the mechanisms of genome stability and the DDR including the most important tumor suppressors such as p53 and PTEN as well as oncogenes such as RAS and MAPK signaling cascades are conserved, the physiology of a cancer, with its different cell types, metastasis, and interactions with the immune system clearly require higher experimental animal models. Despite these limitations, the worm keeps its promise of a simple metazoan 3R-compliant model that allows the understanding of fundamental and novel phenomena at the whole-organism scale.

Guidelines for choosing a 3R-compliant alternative animal model

Despite the many advances in developing improved and more sophisticated *in silico* and *in vitro* models, ranging from the implementation of more physiologically relevant media and growth patterns (e.g., 3D, organoids) to AI-guided molecular predictions, animal models are still indispensable to characterize and recapitulate the complex nature of cancer. Indeed, mammalian models—predominantly rodents—have played a crucial role in elucidating the causes and mechanisms of human cancers, helping characterize phenotypic hallmarks, and enabling the preclinical evaluation of existing and experimental drugs [326, 327]. The advantages and inherent limitations of

murine cancer models, particularly regarding translational relevance and species-specific differences, have been thoroughly reviewed elsewhere [328, 329]. Importantly, questions requiring long-term tumor evolution, complex pharmacokinetics, intact adaptive immunity, or higher-order neuroendocrine regulation may still necessitate rodent—and in specific cases primate—models to capture organism-level physiology [328, 330, 331]. Nonetheless, the disadvantages of rodent models as well as the necessary implementation of the 3R principle has encouraged the use of simpler model organisms to not only reduce ethical concerns but also promote efficient experimentation while yielding clinically relevant results at lower costs and faster experimental timelines.

Selecting an appropriate animal model depends on the biological question (Fig. 5): For dissecting conserved mechanisms such as apoptosis or genome maintenance, invertebrate models like *C. elegans* and *Drosophila* offer powerful genetic tools, fast generation times, and single-cell resolution. *C. elegans* is particularly suited for studying DNA repair, genome integrity, and apoptosis at high cellular resolution, while *Drosophila* offers precise options for modeling complex tumor genetics, tissue-specific transformation, and drug screening. When tissue organization, tumor heterogeneity, or invasion are of interest, vertebrate systems like zebrafish or the avian CAM model are more suitable due to their complex physiology and compatibility with xenotransplantation. Zebrafish provide a genetically tractable vertebrate system with whole-organism imaging and transgenesis, whereas the avian CAM model excels in short-term, medium-throughput xenograft assays with minimal required infrastructure. Importantly, it should be noted that the degree of genetic conservation described for each model reflects the specific experimental needs and constraints of the respective research communities rather than a uniform measure of proximity to human biology.

For large-scale drug or genetic screens, models with short life cycles and simple husbandry—such as *C. elegans*, *Drosophila*, and zebrafish embryos—enable high-throughput experimentation. If the research involves microbiota host-tumor interactions, or pharmacokinetics, systems with intact physiology like zebrafish or CAM—or leveraging bacteria in combination with *C. elegans*—provide greater translational relevance. In practice, the complementary use of models often yields the most robust insight across molecular, cellular, and organismal levels.

Beyond mechanistic suitability, an important selection criterion is predictive validity—i.e., whether responses observed in the model correlate with patient




Fig. 5 Comparative experimental characteristics of different animal cancer models. Overview of advantages (+) and disadvantages (-) of the avian CAM, zebrafish, *Drosophila*, *C. elegans*, and mouse models in cancer research. Created in BioRender (<https://BioRender.com>)

outcomes. Importantly, evidence levels differ: some platforms enable patient-matched therapy testing (same regimen tested in the model), whereas others primarily infer putative sensitivities from genetic alterations or pathway dependencies. Translational validity, evidence levels, turnaround times, and key constraints of the discussed model systems are covered in dedicated reviews for interested readers (avian embryo [97, 332]; zebrafish [181, 183]; *Drosophila* [227, 229]; *C. elegans* [333, 334]; rodents [335–337]; different *in vitro* and *in vivo* model systems [338, 339]).

Overall, emerging tools in genome editing, single-cell analysis, and live imaging are unlocking new potential in 3R-aligned models, broadening their impact from basic discovery to clinical application. Leveraging each model's unique features will foster an efficient and 3R-compliant future for cancer research.

Authors' contributions

T.F., R.A., and F.C.A. wrote the chapters 'Introduction', 'Non-animal models', 'Chorioallantoic membrane model (CAM)', and 'Guidelines for choosing a 3R-compliant alternative animal model'; J.F.A. wrote the chapter 'Zebrafish'; T.R. wrote the chapter 'Drosophila'; B.S. wrote the chapter 'C. elegans'. T.F., T.G.P.G., and F.C.A. revised the manuscript. All authors reviewed, read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. T.F., and R.A. were supported by the German Academic Scholarship Foundation. In addition, T.F. was supported by a scholarship from the Heinrich F.C. Behr foundation, and R.A. by the German Cancer Aid through the 'Mildred-Scheel-Doctoral Program'. T.R. acknowledges funding from Wilhelm Sander-Stiftung (2018.145.1), German Cancer Aid (70115333, 70116491/70116492), German Research Foundation (RE 3453/2 – 1, RE 3453/6 – 1, DFG INST208/539-1

FUGG), and José Carreras Leukaemia Foundation (DJCLS 14R/2024). J.F.A. was supported by grants P30CA014089 and U54CA231649 from the US National Cancer Institute. B.S. acknowledges funding from the European Research Council (ERC-2023-SyG, 101118919), the Hevolution Foundation (HF-GRO-23-1199212-35), the Deutsche Forschungsgemeinschaft (Reinhart Koselleck-Projekt 524088035, FOR 5504 project 496650118, FOR 5762 project 531902955, SFB 1678, SFB 1607, CECAD EXC 2030–390661388, DFG-ISF project 561031107, ANR-DFG project 545378328, and the DFG project grants 558166204, 540136447, 496914708, 437825591, 437407415, 418036758), the José Carreras Leukemia Foundation (DJCLS 04 R/2023), the Deutsche Krebshilfe (70114555), and the John Templeton Foundation Grant (61734). T.G.P.G. and F.C.A. acknowledge funding from the Matthias-Lackas foundation, the Dr. Leopold und Carmen Ellinger foundation, Dr. Rolf M. Schwiete foundation (2021-007; 2022-031), the German Cancer Aid (DKH-70115315, DKH-70114278, DKH-70115914), the German Cancer Consortium (DKTK, PredictAHR), the SMARCB1 association, the Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA), the KiKa foundation, the Fight Kids Cancer foundation (FKC-NEWTARGETS), the KITZ-Foundation in memory of Kirstin Diehl, the KITZ-PMC twinning program, Sarcoma Research UK, the Barbara and Wilfried Mohr foundation, and the European Union (ERC, CANCER-HARAKIRI, 101122595). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or the European Research Council (ERC). Neither the European Union nor the granting authority can be held responsible for them.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The image displayed in Fig. 2C-E was originally published in Vasileva E, Warren M, Triche TJ, Amatruda JF. Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth. *Elife*. 2022 Mar 14;11:e69734, copyright © 2022, Vasileva et al. This article is distributed under the terms of the Creative

Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Competing interests

The authors declare no competing interests.

Received: 6 November 2025 / Accepted: 29 January 2026

Published online: 26 March 2026

References

1. Russell WMS, Burch RL. The principles of humane experimental technique. Universities Federation for Animal Welfare; 1959. <https://caat.jhsph.edu/the-principles-of-humane-experimental-technique-2/>.
2. Rumpel S, Kempen R, Merle R, Thoenes-Reineke C. Psychological stress and strain in laboratory animal professionals – a systematic review. *Lab Anim*. 2023;57:396–411.
3. Petetta F, Ciccocioppo R. Public perception of laboratory animal testing: Historical, philosophical, and ethical view. *Addict Biol*. 2021;26:e12991.
4. Olsson IAS, Silva SP, da Townsend D, Sandøe P. Protecting animals and enabling research in the European union: an overview of development and implementation of directive 2010/63/EU. *ILAR J*. 2016;57:347–57.
5. Brown MJ, et al. Culture of care: organizational responsibilities. In: Weichbrodt RH, Thompson GA, Heidbrink, Norton JN, editors. *Management of animal care and use programs in Research, Education, and testing*. CRC Press/Taylor & Francis; 2018. <http://www.ncbi.nlm.nih.gov/books/NBK500402/>.
6. Prescott MJ, Lidster K. Improving quality of science through better animal welfare: the NC3Rs strategy. *Lab Anim*. 2017;46:152–6.
7. LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. Next-generation cancer organoids. *Nat Mater*. 2022;21:143–59.
8. Decaestecker C, Debeir O, Van Ham P, Kiss R. Can anti-migratory drugs be screened *in vitro*? A review of 2D and 3D assays for the quantitative analysis of cell migration. *Med Res Rev*. 2007;27:149–76.
9. Association of Medical Research Charities (AMRC). Position statement on the use of animals in research. Association Med Res Charities <https://www.amrc.org.uk/position-statement-on-the-use-of-animals-in-research> (2019).
10. White R, Rose K, Zon L. Zebrafish cancer: the state of the Art and the path forward. *Nat Rev Cancer*. 2013;13:624–36.
11. Nascimento-Gonçalves E, Ferreira R, Oliveira PA, Colaço BJ. A. An overview of current alternative models for use in the context of prostate cancer research. *Altern Lab Anim*. 2020;48:58–69.
12. National Centre for the Replacement, Refinement & Reduction of Animals in Research. The 3Rs | NC3Rs. (2025). <https://nc3rs.org.uk/who-we-are/3rs>
13. Strähle U, et al. Zebrafish embryos as an alternative to animal experiments—A commentary on the definition of the onset of protected life stages in animal welfare regulations. *Reprod Toxicol*. 2012;33:128–32.
14. United States of America. Animal Welfare Act. 2018. <https://www.ecfr.gov/current/title-9/chapter-I/subchapter-A>.
15. CCAC. CCAC - Canadian Council on Animal Care. *CCAC - Canadian Council on Animal Care* <https://ccac.ca/en/guidelines-and-policies/the-guidelines/types-of-animal-guidelines.html>
16. Directive. 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. 2019. <http://data.europa.eu/eli/dir/2010/63/2019-06-26/eng>.
17. Hollands C. The animals (Scientific Procedures) act 1986. *Lancet*. 1986;328:32–3.
18. Ogden BE, Pang W, Agui T, Lee BH. Laboratory Animal Laws, Regulations, Guidelines and Standards in China Mainland, Japan, and Korea. *ILAR Journal* 57, 301–311 (2016).
19. Rous P. A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT. SEPARABLE FROM THE TUMOR CELLS. *J Exp Med*. 1911;13:397–411.
20. Ossowski L, Reich E. Experimental Model for Quantitative Study of Metastasis. *Cancer Res*. 1980;40(7):2300–9. <https://aacrjournals.org/cancerres/article/40/7/2300/484869/Experimental-Model-for-Quantitative-Study-of>.
21. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. *Cell*. 1988;52:321–8.
22. Stark MB. A benign tumor that is hereditary in drosophila. *Proc Natl Acad Sci U S A*. 1919;5:573–80.
23. Bellen HJ, Tong C, Tsuda H. 100 years of drosophila research and its impact on vertebrate neuroscience: a history lesson for the future. *Nat Rev Neurosci*. 2010;11:514–22.
24. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and Polarity in drosophila. *Nature*. 1980;287:795–801.
25. Nüsslein-Volhard C. The identification of genes controlling development in flies and fishes (Nobel Lecture). *Angewandte Chemie Int Ed Engl*. 1996;35:2176–87.
26. Potter CJ, Turenchalk GS, Xu T. Drosophila in cancer research. An expanding role. *Trends Genet*. 2000;16:33–9.
27. Gonzalez C. Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. *Nat Rev Cancer*. 2013;13:172–83.
28. Zhan T, et al. Zebrafish live imaging: a strong weapon in anticancer drug discovery and development. *Clin Transl Oncol*. 2024;26:1807–35.
29. Hason M, Bartůňek P. Zebrafish models of cancer—New insights on modeling human cancer in a Non-Mammalian vertebrate. *Genes*. 2019;10:935.
30. Pliss GB, Zabezhinski MA, Petrov AS, Khudoley VV. Peculiarities of N-nitramines carcinogenic action. *Arch Geschwulstforsch*. 1982;52:629–34.
31. Haffter P, et al. The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. *Development*. 1996;123:1–36.
32. Horvitz HR. Worms, life, and death (Nobel lecture). *ChemBioChem*. 2003;4:697–711.
33. Sulston JE. Post-embryonic development in the ventral cord of caenorhabditis elegans. *Philos Trans R Soc Lond B Biol Sci*. 1976;275:287–97.
34. Galuschka C, Proynova R, Roth B, Augustin HG, Müller-Decker K. Models in translational oncology: A public resource database for preclinical cancer research. *Cancer Res*. 2017;77:2557–63.
35. Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM. Characteristics of in vivo model systems for ovarian cancer studies. *Diagnostics*. 2019;9:120.
36. Giusti V, et al. Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research. *Biomedicines*. 2024;12(8):1921. <https://doi.org/10.3390/biomedicines12081921>.
37. Sys G, et al. Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick Chorioallantoic membrane model. *Cancer Lett*. 2012;326:69–78.
38. Creemers JHA, et al. In Silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. *Nat Commun*. 2023;14:1–14.
39. Nürnberg E, et al. From in vitro to in silico: a pipeline for generating virtual tissue simulations from real image data. *Front Mol Biosci*. 2024;11:1467366. <https://doi.org/10.3389/fmolb.2024.1467366>.
40. Arabameri A, Arab S. Understanding the interplay of CAR-NK cells and Triple-Negative breast cancer: insights from computational modeling. *Bull Math Biol*. 2024;86:20.
41. Kolokotroni E, et al. A multidisciplinary Hyper-Modeling scheme in personalized in Silico oncology: coupling cell kinetics with Metabolism, signaling Networks, and biomechanics as Plug-In component models of a cancer digital twin. *J Personalized Med*. 2024;14:475.
42. Meyerheim M, et al. Exploring the in Silico adaptation of the nephroblastoma oncosimulator to MRI scans, treatment data, and histological profiles of patients from different risk groups. *Front Physiol*. 2025;16:1465631.
43. Orth MF, et al. Systematic multi-omics cell line profiling uncovers principles of ewing sarcoma fusion oncogene-mediated gene regulation. *Cell Rep*. 2022;41(10):111761. <https://doi.org/10.1016/j.celrep.2022.111761>.
44. Abbas ZN, Al-Saffar AZ, Jasim SM, Sulaiman GM. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. *Sci Rep*. 2023;13:18380.
45. Ceranski AK, et al. Hypoxia and HIFs in ewing sarcoma: new perspectives on a multi-faceted relationship. *Mol Cancer*. 2023;22:49.
46. Kasan M, et al. Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines. *Nat Commun*. 2025;16:380.
47. Ben-David U, et al. Genetic and transcriptional evolution alters cancer cell line drug response. *Nature*. 2018;560:325–30.
48. Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? *Front Mol Biosci*. 2020;7:33. <https://doi.org/10.3389/fmolb.2020.00033>.
49. Fontoura JC, et al. Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance. *Mater Sci Engineering: C*. 2020;107:110264.
50. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? *Acta Pharm Sinica B*. 2022;12:3049–62.

51. Habanjar O, Diab-Assaf M, Caldefie-Chez F, Delort L. 3D cell culture systems: tumor Application, Advantages, and disadvantages. *Int J Mol Sci*. 2021;22:12200.
52. De Cock L, et al. Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group. *Neoplasia*. 2025;65:101171.
53. Law AMK, et al. Advancements in 3D cell culture systems for personalizing Anti-Cancer therapies. *Front Oncol*. 2021;11:782766. <https://doi.org/10.3389/fonc.2021.782766>.
54. van Marion DMS, Domanska UM, Timmer-Bosscha H, Walenkamp AM. E. Studying cancer metastasis: existing models, challenges and future perspectives. *Crit Rev Oncol/Hematol*. 2016;97:107–17.
55. Cordeiro S, et al. Breaking the mold: 3D cell cultures reshaping the future of cancer research. *Front Cell Dev Biol*. 2024;12:1507388.
56. Avula LR, Grodzinski P. How organ-on-a-chip is advancing cancer research and oncology - a cancer hallmarks' perspective. *Front Lab Chip Technol*. 2024;3. <https://doi.org/10.3389/frlct.2024.1487377>.
57. Colombo MV, et al. A vascularized microphysiological system reproducing endochondral ossification in vitro to study ewing sarcoma proliferation and migration. *Adv Funct Mater*. 2025;e18470. <https://doi.org/10.1002/adfm.202418470>.
58. Visalakshan RM, et al. Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions. *Front Immunol*. 2023;14:1162905.
59. Srivastava SK, Foo GW, Aggarwal N, Chang MW. Organ-on-chip technology: opportunities and challenges. *Biotechnol Notes*. 2024;5:8–12.
60. Fan X, et al. Strategies to overcome the limitations of current organoid technology - engineered organoids. *J Tissue Eng*. 2025;16:20417314251319475.
61. Ceranski AK, et al. Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in ewing sarcoma spheroids. *Cell Rep Methods*. 2025;100966. <https://doi.org/10.1016/j.crmeth.2025.100966>.
62. Goldrick C, et al. 3D multicellular systems in disease modelling: from organoids to organ-on-chip. *Front Cell Dev Biol*. 2023;11:1083175. <https://doi.org/10.3389/fcell.2023.1083175>.
63. Kumar D, Nadda R, Repaka R. Advances and challenges in organ-on-chip technology: toward mimicking human physiology and disease in vitro. *Med Biol Eng Comput*. 2024;62:1925–57.
64. Fischer D, et al. The CAM Model—Q&A with experts. *Cancers (Basel)*. 2022;15:191.
65. Hamburger V, Hamilton HL. A series of normal stages in the development of the chick embryo. *Dev Dyn*. 1992;195:231–72.
66. Ribatti D. The chick embryo Chorioallantoic membrane patient-derived xenograft (PDX) model. *Pathol - Res Pract*. 2023;243:154367.
67. Crespo P, Casar B. The Chick Embryo Chorioallantoic Membrane as an in vivo Model to Study Metastasis. *BIO-PROTOCOL*. 2016;6. <https://doi.org/10.21769/BioProtoc.1962>.
68. Kunz P, Schenker A, Sähr H, Lehner B, Fellenberg J. Optimization of the chicken Chorioallantoic membrane assay as reliable in vivo model for the analysis of osteosarcoma. *PLoS ONE*. 2019;14:e0215312.
69. Mosna MJ, Garde FJ, Stinson MG, Pastore CD, Carcagno AL. The Chorioallantoic membrane (CAM) model: from its origins in developmental biology to its role in cancer research. *Dev Biol*. 2025;519:79–95.
70. Chu P-Y, Koh AP-F, Antony J, Huang RY-J. Applications of the chick Chorioallantoic membrane as an alternative model for cancer studies. *CTO*. 2022;211:222–37.
71. Li A, et al. Mesenchymal-endothelial nexus in breast cancer spheroids induces vasculogenesis and local invasion in a CAM model. *Commun Biol*. 2022;5:1–15.
72. Wan Z, Hirche C, Fricke F, Dragu A, Will PA. Chick Chorioallantoic membrane as an in vivo model for the study of angiogenesis and lymphangiogenesis. *J Vasc Res*. 2024;62:109–20.
73. Li Z, et al. Application of animal models in cancer research: recent progress and future prospects. *CMAR*. 2021;13:2455–75.
74. Fellenberg J, Losch S, Tripel E, Lehner B, Melnik S. The Warburg trap: A novel therapeutic approach for targeting osteosarcoma. *Cells*. 2023;13:61.
75. Harper K, et al. The chicken Chorioallantoic membrane tumor assay as a relevant in vivo model to study the impact of hypoxia on tumor progression and metastasis. *Cancers (Basel)*. 2021;13:1093.
76. Kim Y, et al. Quantification of cancer cell extravasation in vivo. *Nat Protoc*. 2016;11:937–48.
77. Niebora J, et al. Avian models for human Carcinogenesis-Recent findings from molecular and clinical research. *Cells*. 2024;13:1797.
78. Kundeková B, Máčajová M, Meta M, Čavarga I, Bilčík B. Chorioallantoic membrane models of various avian species: differences and applications. *Biology (Basel)*. 2021;10:301.
79. Pomraenke M, et al. A novel breast cancer xenograft model using the ostrich Chorioallantoic Membrane—A proof of concept. *Vet Sci*. 2023;10:349.
80. Rovithi M, et al. Development of bioluminescent chick Chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. *Sci Rep*. 2017;7:44686.
81. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov*. 2022;12:31–46.
82. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100:57–70.
83. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–74.
84. Guder WK, et al. 5-ALA-mediated fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model: preclinical in vivo qualification analysis as a fluorescence-guided surgery agent in orthopedic oncology. *J Orthop Surg Res*. 2022;17:34.
85. Bobek V, et al. Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model. *Clin Exp Metastasis*. 2004;21:347–52.
86. Jefferies B, et al. Non-invasive imaging of engineered human tumors in the living chicken embryo. *Sci Rep*. 2017;7:4991.
87. Annese T, Tamma R, Ribatti D. IKOSA® CAM Assay Application to Quantify Blood Vessels on Chick Chorioallantoic Membrane (CAM). Tumor angiogenesis assays: methods and protocols. Springer US; 2023. pp. 129–39. https://doi.org/10.1007/978-1-0716-2703-7_10.
88. Pion E, Haerteis S, Aung T. Application of laser speckle contrast imaging (LSCI) for the angiogenesis measurement of tumors in the Chorioallantoic membrane (CAM) model. In: Ribatti D vol, editor. Tumor angiogenesis assays. Volume 2572. Springer US; 2023. pp. 141–53.
89. Smith LM, et al. The chicken Chorioallantoic membrane as a low-cost, high-throughput model for cancer imaging. *Npj Imaging*. 2023;1:1–12.
90. van der Horst EH, Leupold JH, Schubbert R, Ullrich A, Allgayer H. TaqMan-based quantification of invasive cells in the chick embryo metastasis assay. *Biotechniques*. 2004;37:940–2.
91. Allgayer H, et al. Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025. *Mol Cancer*. 2025;24:167.
92. Winter G, et al. In vivo PET/MRI imaging of the Chorioallantoic membrane. *Front Phys*. 2020;8. <https://doi.org/10.3389/fphy.2020.00151>.
93. Eckrich J, et al. Monitoring of tumor growth and vascularization with repetitive ultrasonography in the chicken chorioallantoic-membrane-assay. *Sci Rep*. 2020;10:18585.
94. Wessendorf J, et al. Feasibility of the chick Chorioallantoic membrane model for preclinical studies on tumor radiofrequency ablation. *Eur Radiol Exp*. 2023;7:56.
95. Deryugina E et al. Neutrophil Elastase Facilitates Tumor Cell Intravasation and Early Metastatic Events. *iScience* 23, 101799 (2020).
96. Brignole C, et al. Effect of bortezomib on human neuroblastoma cell Growth, Apoptosis, and angiogenesis. *JNCI: J Natl Cancer Inst*. 2006;98:1142–57.
97. Vu BT, et al. Chick Chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. *Sci Rep*. 2018;8:8524.
98. Estienne A, et al. Chemerin is secreted by the chicken oviduct, accumulates in egg albumen and could promote embryo development. *Sci Rep*. 2022;12:8989.
99. Kue CS, Tan KY, Lam ML, Lee HB. Chick embryo Chorioallantoic membrane (CAM): an alternative predictive model in acute toxicological studies for anti-cancer drugs. *Exp Anim*. 2015;64:129–38.
100. Ribeiro LNM, Schlemper AE, da Silva MV, Fonseca BB. Chicken embryo: a useful animal model for drug testing? *Eur Rev Med Pharmacol Sci*. 2022;26:4828–39.
101. Hadjimichael C, Kardamak D, Papaioannou S. Irradiation Dose-response effects on angiogenesis and involvement of nitric oxide. *Anticancer Res*. 2005;25:1059–65.
102. Dünker N, Jendrosseck V. Implementation of the chick Chorioallantoic membrane (CAM) model in radiation biology and experimental radiation oncology research. *Cancers (Basel)*. 2019;11:1499.
103. Huang W-T, et al. Effect of miR-146a-5p on tumor growth in NSCLC using chick Chorioallantoic membrane assay and bioinformatics investigation. *Mol Med Res*. 2017;16:8781–92.

104. Krutzke L, Allmendinger E, Hirt K, Kochanek S. Chorioallantoic membrane tumor model for evaluating oncolytic viruses. *Hum Gene Ther*. 2020;31:1100–13.
105. Pawlikowska P, et al. Exploitation of the chick embryo Chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing. *Sci Rep*. 2020;10:16876.
106. Nowak-Sliwinska P, Segura T, Iruela-Arispe ML. The chicken Chorioallantoic membrane model in biology, medicine and bioengineering. *Angiogenesis*. 2014;17:779–804.
107. Kerkhoff M, et al. Evaluation of the effect of photodynamic therapy on CAM-Grown sarcomas. *Bioengineering*. 2023;10:464.
108. Ribatti D. *The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis* Springer Netherlands, (2010). <https://doi.org/10.1007/978-90-481-3845-6>
109. Miebach L, Berner J, Bekeschus S. In Ovo model in cancer research and tumor immunology. *Front Immunol*. 2022;13:1006064. <https://doi.org/10.3389/fimmu.2022.1006064>.
110. Janković BD, et al. Immunological capacity of the chicken embryo. I. Relationship between the maturation of lymphoid tissues and the occurrence of cell-mediated immunity in the developing chicken embryo. *Immunology*. 1975;29:497–508.
111. Nipper AJ, et al. Chick embryo Chorioallantoic membrane as a platform for assessing the in vivo efficacy of chimeric antigen receptor T-cell therapy in solid tumors. *ImmunoHorizons*. 2024;8:598–605.
112. Wang Y, et al. PD-1/PD-L1 checkpoint inhibitors are active in the chicken embryo model and show antitumor efficacy in Ovo. *Cancers*. 2022;14:3095.
113. Charbonneau M, et al. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glioma tumors. *Neuro Oncol*. 2023;25:1605–16.
114. Pizon M, et al. Chick Chorioallantoic membrane (CAM) assays as a model of Patient-Derived xenografts from Circulating cancer stem cells (cCSCs) in breast cancer patients. *Cancers*. 2022;14:1476.
115. Wagner BJ, et al. Patient-derived xenografts from Circulating cancer stem cells as a preclinical model for personalized pancreatic cancer research. *Sci Rep*. 2025;15:2896.
116. Roussel X, et al. Embryonated chicken tumor xenografts derived from Circulating tumor cells as a relevant model to study metastatic dissemination: A proof of concept. *Cancers (Basel)*. 2022;14:4085.
117. Barnabas GD, et al. Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe. *EMBO Mol Med*. 2025;17:625–44.
118. Grunwald DJ, Streisinger G. Induction of recessive lethal and specific locus mutations in the zebrafish with Ethyl nitrosourea. *Genet Res*. 1992;59:103–16.
119. Streisinger G, Walker C, Dower N, Knauber D, Singer F. Production of clones of homozygous diploid zebra fish (*Brachydanio rerio*). *Nature*. 1981;291:293–6.
120. Driever W, et al. A genetic screen for mutations affecting embryogenesis in zebrafish. *Development*. 1996;123:37–46.
121. Howe K, et al. The zebrafish reference genome sequence and its relationship to the human genome. *Nature*. 2013;496:498–503.
122. Dooley K, Zon LI. Zebrafish: a model system for the study of human disease. *Curr Opin Genet Dev*. 2000;10:252–6.
123. Detrich HW, Westerfield M. Zon, L. I. Overview of the zebrafish system. *Methods Cell Biol*. 1999;59:3–10.
124. Menke AL, Spitsbergen JM, Wolterbeek APM, Woutersen RA. Normal anatomy and histology of the adult zebrafish. *Toxicol Pathol*. 2011;39:759–75.
125. Langenau DM, et al. Myc-induced T cell leukemia in Transgenic zebrafish. *Science*. 2003;299:887–90.
126. Patton EE, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. *Curr Biol*. 2005;15:249–54.
127. McGrail M, et al. Somatic mutagenesis with a sleeping beauty transposon system leads to solid tumor formation in zebrafish. *PLoS ONE*. 2011;6:e18826.
128. Suster ML, Kikuta H, Urasaki A, Asakawa K, Kawakami K. Transgenesis in zebrafish with the tol2 transposon system. *Methods Mol Biol*. 2009;561:41–63.
129. Mayrhofer M, Mione M. The toolbox for conditional zebrafish cancer models. *Adv Exp Med Biol*. 2016;916:21–59.
130. Callahan SJ, et al. Cancer modeling by transgene electroporation in adult zebrafish (TEAZ). *Dis Model Mech*. 2018;11:dmm034561.
131. Le X, et al. Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in Transgenic zebrafish. *Proc Natl Acad Sci U S A*. 2007;104:9410–5.
132. Zhu S, Thomas Look A. Neuroblastoma and its zebrafish model. *Adv Exp Med Biol*. 2016;916:451–78.
133. Kendall GC, et al. PAX3-FOXO1 Transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. *Elife*. 2018;7:e33800.
134. Langenau DM, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. *Genes Dev*. 2007;21:1382–95.
135. Vasileva E, Warren M, Triche TJ, Amatruda JF. Dysregulated Heparan sulfate proteoglycan metabolism promotes ewing sarcoma tumor growth. *Elife*. 2022;11:e69734.
136. Leacock SW, et al. A zebrafish Transgenic model of ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. *Dis Model Mech*. 2012;5:95–106.
137. Nguyen AT, et al. An inducible kras(V12) Transgenic zebrafish model for liver tumorigenesis and chemical drug screening. *Dis Model Mech*. 2012;5:63–72.
138. Ju B, et al. Oncogenic KRAS promotes malignant brain tumors in zebrafish. *Mol Cancer*. 2015;14:18.
139. Jung IH, et al. Glioma is formed by active Akt1 alone and promoted by active Rac1 in Transgenic zebrafish. *Neuro Oncol*. 2013;15:290–304.
140. Casey MJ, Stewart RA. Pediatric cancer models in zebrafish. *Trends Cancer*. 2020;6:407–18.
141. Zhu S, et al. LMO1 synergizes with MYCN to promote neuroblastoma initiation and metastasis. *Cancer Cell*. 2017;32:310–e3235.
142. Ceol CJ, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. *Nature*. 2011;471:513–7.
143. Vasileva E, et al. Origin of ewing sarcoma by embryonic reprogramming of neural crest to mesoderm. *BioRxiv*. 2024;20241027620438. <https://doi.org/10.1101/2024.10.27.620438>.
144. Kendall GC, Amatruda JF. Zebrafish as a model for the study of solid malignancies. *Methods Mol Biol*. 2016;1451:121–42.
145. Spitsbergen JM, et al. Neoplasia in zebrafish (*Danio rerio*) treated with 7,12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. *Toxicol Pathol*. 2000;28:705–15.
146. Amatruda JF, Shepard JL, Stern HM, Zon, L. I. Zebrafish as a cancer model system. *Cancer Cell*. 2002;1:229–31.
147. Nicoli S, Ribatti D, Cotelli F, Presta M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. *Cancer Res*. 2007;67:2927–31.
148. Castranova D, et al. Live imaging of intracranial lymphatics in the zebrafish. *Circ Res*. 2021;128:42–58.
149. Yaniv K, et al. Live imaging of lymphatic development in the zebrafish. *Nat Med*. 2006;12:711–6.
150. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using Transgenic zebrafish. *Dev Biol*. 2002;248:307–18.
151. Sturtzel C, et al. Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts. *NPJ Precis Oncol*. 2023;7:44.
152. Linsley JW, Reisine T, Finkbeiner S. Three dimensional and four dimensional live imaging to study mechanisms of progressive neurodegeneration. *J Biol Chem*. 2024;300:107433.
153. Zhang G, et al. Mitochondrial UQC3 controls embryonic and tumor angiogenesis by regulating VEGF expression. *iScience*. 2023;26:107370.
154. de Rebelo C, et al. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. *Commun Biol*. 2020;3:299.
155. Chiavacci E, et al. The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. *Cytotechnology*. 2015;67:969–75.
156. Chimote G, et al. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. *Drug Des Devel Ther*. 2014;8:1107–23.
157. Yan C, Yang Q, Do D, Brunson DC, Langenau DM. Adult immune compromised zebrafish for xenograft cell transplantation studies. *EBioMedicine*. 2019;47:24–6.
158. White RM, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. *Cell Stem Cell*. 2008;2:183–9.
159. Verduzco D, Amatruda JF. Analysis of cell proliferation, senescence, and cell death in zebrafish embryos. *Methods Cell Biol*. 2011;101:19–38.
160. Hunter MV, Moncada R, Weiss JM, Yanai I, White RM. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. *Nat Commun*. 2021;12:6278.
161. Neumann JC, Dovey JS, Chandler GL, Carbajal L, Amatruda JF. Identification of a heritable model of testicular germ cell tumor in the zebrafish. *Zebrafish*. 2009;6:319–27.

162. Chen C-H, Durand E, Wang J, Zon LI, Poss K. D. zebrafish Transgenic lines for in vivo bioluminescence imaging of stem cells and regeneration in adult zebrafish. *Development*. 2013;140:4988–97.
163. Hamilton N, Allen C, Reynolds S. Longitudinal MRI brain studies in live adult zebrafish. *NMR Biomed*. 2023;36:e4891.
164. Tucker C, Collins R, Denvir MA, McDougald W. A. PET/CT technology in adult zebrafish: A pilot study toward live longitudinal imaging. *Front Med (Lausanne)*. 2021;8:725548.
165. Martinez-Lopez M, Póvoa V, Fior R. Generation of zebrafish larval xenografts and tumor behavior analysis. *J Vis Exp*. 2021. <https://doi.org/10.3791/62373>.
166. He F, Tu L, Chan L, Leung A, Sun X. Optimized intravenous injection in adult zebrafish. *J Vis Exp*. 2024. <https://doi.org/10.3791/67463>.
167. Collymore C, Rasmussen S, Tolwani RJ. Gavage adult zebrafish. *J Vis Exp*. 2013;50691. <https://doi.org/10.3791/50691>.
168. Cocchiaro JL, Rawls JF. Microgavage of zebrafish larvae. *J Vis Exp*. 2013;e4434. <https://doi.org/10.3791/4434>.
169. Lu Y, Patton EE. Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance. *Dis Model Mech*. 2022;15:dmm049401.
170. Peterson RT, et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. *Nat Biotechnol*. 2004;22:595–9.
171. Yoganantharajah P, Gilbert Y. The use of the zebrafish model to aid in drug discovery and target validation. *Curr Top Med Chem*. 2017;17:2041–55.
172. Epperly MW, Bahary N, Quader M, Dewald V, Greenberger JS. The zebrafish–Danio rerio—is a useful model for measuring the effects of small-molecule mitigators of late effects of ionizing irradiation. *Vivo*. 2012;26:889–97.
173. Xu T, et al. Leveraging zebrafish models for advancing radiobiology: Mechanisms, applications, and future prospects in radiation exposure research. *Environ Res*. 2025;266:120504.
174. Costa B, et al. Developments in zebrafish avatars as radiotherapy sensitivity reporters - towards personalized medicine. *EBioMedicine*. 2020;51:102578.
175. Pascoal S, et al. A preclinical embryonic zebrafish xenograft model to investigate CAR T cells in vivo. *Cancers (Basel)*. 2020;12:567.
176. Pattipeiluhu R, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. *Adv Mater*. 2022;34:e2201095.
177. Yan C, et al. Single-cell imaging of T cell immunotherapy responses in vivo. *J Exp Med*. 2021;218:e20210314.
178. Androuin A, Verweij FJ, van Niel G. Zebrafish as a preclinical model for extracellular Vesicle-based therapeutic development. *Adv Drug Deliv Rev*. 2021;176:113815.
179. Pawar N, et al. Abstract 4704: development of a novel zebrafish patient-derived xenograft (zPDX) platform for functional precision cancer medicine for immune checkpoint (ICIs) and tyrosine kinase inhibitors (TKIs) of renal cell carcinoma (RCC). *Cancer Res*. 2025;85:4704.
180. Nishimura Y, et al. Zebrafish as a systems toxicology model for developmental neurotoxicity testing. *Congenit Anom (Kyoto)*. 2015;55:1–16.
181. Costa B, Estrada MF, Mendes RV, Fior R. Zebrafish avatars towards personalized Medicine-A comparative review between avatar models. *Cells*. 2020;9:293.
182. Fior R, et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. *Proc Natl Acad Sci U S A*. 2017;114:E8234–43.
183. Fazio M, Ablain J, Chuan Y, Langenau DM, Zon, L. I. Zebrafish patient avatars in cancer biology and precision cancer therapy. *Nat Rev Cancer*. 2020;20:263–73.
184. Yan C, et al. Single-cell imaging of human cancer xenografts using adult immunodeficient zebrafish. *Nat Protoc*. 2020;15:3105–28.
185. Varanda AB, Martins-Logrado A, Ferreira MG, Fior R. Zebrafish xenografts unveil sensitivity to Olaparib beyond BRCA status. *Cancers (Basel)*. 2020;12:1769.
186. Corsinovi D, Usai A, Sarlo MD, Giannaccini M, Ori M. Zebrafish avatar to develop precision breast cancer therapies. *Anticancer Agents Med Chem*. 2022;22:748–59.
187. Song F, et al. Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer. *Drug Resist Updates*. 2025;78:101162.
188. Lindahl G, et al. Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer. *Npj Precis Onc*. 2024;8:53.
189. Póvoa V, et al. Innate immune evasion revealed in a colorectal zebrafish xenograft model. *Nat Commun*. 2021;12:1156.
190. Mercatali L, et al. Development of a Patient-Derived xenograft (PDX) of breast cancer bone metastasis in a zebrafish model. *Int J Mol Sci*. 2016;17:1375.
191. Ali Z, et al. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. *J Exp Clin Cancer Res*. 2022;41:58.
192. Costa B, et al. Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer. *Nat Commun*. 2024;15:4771.
193. Mendes RV, et al. Zebrafish avatar testing preclinical study predicts chemotherapy response in breast cancer. *NPJ Precis Oncol*. 2025;9:94.
194. Leslie M. Fish implanted with tumor cells could help oncologists quickly personalize cancer treatments. (2025) <https://doi.org/10.1126/science.z63yktc>
195. Rajan V, et al. Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity. *Haematologica*. 2020;105:2391–9.
196. Bier E. *Drosophila*, the golden bug, emerges as a tool for human genetics. *Nat Rev Genet*. 2005;6:9–23.
197. Pandey UB, Nichols CD. Human disease models in *drosophila melanogaster* and the role of the fly in therapeutic drug discovery. *Pharmacol Rev*. 2011;63:411–36.
198. Morgan TH. Sex limited inheritance in *drosophila*. *Science*. 1910;32:120–2.
199. Harvey KF, Pfeiffer CM, Hariharan IK. The *drosophila* Mst Ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. *Cell*. 2003;114:457–67.
200. Dexter JS. The analysis of a case of continuous variation in *drosophila* by a study of its linkage relations. *Am Nat*. 1914;48:712–58.
201. Sharma RP, Chopra VL. Effect of the wingless (wg1) mutation on wing and haltere development in *drosophila melanogaster*. *Dev Biol*. 1976;48:461–5.
202. Ugur B, Chen K, Bellen HJ. *Drosophila* tools and assays for the study of human diseases. *Dis Model Mech*. 2016;9:235–44.
203. Mirzoyan Z, et al. *Drosophila melanogaster*: A model organism to study cancer. *Front Genet*. 2019;10:51. <https://doi.org/10.3389/fgene.2019.00051>.
204. Dawson EH, et al. Social environment mediates cancer progression in *drosophila*. *Nat Commun*. 2018;9:3574.
205. Sonoshita M, Cagan RL. Modeling human cancers in *drosophila*. In: Pick L vol, editor. Current topics in developmental biology. Volume 121. Academic; 2017. pp. 287–309.
206. Bilder D, Ong K, Hsi T-C, Adiga K, Kim J. Tumour–host interactions through the lens of *drosophila*. *Nat Rev Cancer*. 2021;21:687–700.
207. Geissler K, Zach O. Pathways involved in *drosophila* and human cancer development: the Notch, Hedgehog, Wingless, Runt, and trithorax pathway. *Ann Hematol*. 2012;91:645–69.
208. Gong S, Zhang Y, Tian A, Deng W-M. Tumor models in various *drosophila* tissues. *WIREs Mech Disease*. 2021;13:e1525.
209. Khan C, Rusan NM. Using *drosophila* to uncover the role of organismal physiology and the tumor microenvironment in cancer. *Trends Cancer*. 2024;10:289–311.
210. Lam Wong KK, Verheyen EM. Metabolic reprogramming in cancer: mechanistic insights from *drosophila*. *Dis Models Mech*. 2021;14:dmm048934.
211. Liu Y, Saavedra P, Perrimon N. Cancer cachexia: lessons from *drosophila*. *Dis Models Mech*. 2022;15:dmm049298.
212. Potter CJ, Turenchalk GS, Xu T. *Drosophila* in cancer research. *Trends Genet*. 2000;16:33–9.
213. Ohlstein B, Spradling A. The adult *drosophila* posterior midgut is maintained by pluripotent stem cells. *Nature*. 2006;439:470–4.
214. Micchelli CA, Perrimon N. Evidence that stem cells reside in the adult *drosophila* midgut epithelium. *Nature*. 2006;439:475–9.
215. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development*. 1993;118:401–15.
216. Duffy JB. GAL4 system in *drosophila*: a fly geneticist's Swiss army knife. *Genesis*. 2002;34:1–15.
217. Pagliarini RA, Xu T. A genetic screen in *drosophila* for metastatic behavior. *Science*. 2003;302:1227–31.
218. Brumby AM, Richardson H. E. scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in *drosophila*. *EMBO J*. 2003;22:5769–79.
219. Pagliarini RA, Quiñones AT, Xu T. Analyzing the function of tumor suppressor genes using a *drosophila* model. In: El-Deiry WS, editor. Tumor suppressor genes: volume 2 Regulation, Function, and medicinal applications. Humana; 2003. pp. 349–82.
220. Sousa-Nunes R, Yee LL, Gould AP. Fat cells reactivate quiescent neuroblasts via TOR and glial insulin relays in *drosophila*. *Nature*. 2011;471:508–12.

221. Xu T, Rubin GM. Analysis of genetic mosaics in developing and adult drosophila tissues. *Development*. 1993;117:1223–37.
222. Lee T, Luo L. Mosaic analysis with a repressible cell marker (MARCM) for drosophila neural development. *Trends Neurosci*. 2001;24:251–4.
223. Rossi F, Gonzalez C. Studying tumor growth in drosophila using the tissue allograft method. *Nat Protoc*. 2015;10:1525–34.
224. Willoughby LF, et al. An in vivo large-scale chemical screening platform using drosophila for anti-cancer drug discovery. *Dis Models Mech*. 2013;6:521–9.
225. Lai S-L, Lee T. Genetic mosaic with dual binary transcriptional systems in drosophila. *Nat Neurosci*. 2006;9:703–9.
226. Potter CJ, Tasic B, Russler EV, Liang L, Luo L. The Q system: a repressible binary system for transgene expression, lineage tracing, and mosaic analysis. *Cell*. 2010;141:536–48.
227. Munnik C, Xaba MP, Malindisa ST, Russell BL, Sooklal SA. Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. *Front Genet*. 2022;13:949241. <https://doi.org/10.3389/fgene.2022.949241>.
228. Gateff E. Malignant neoplasms of genetic origin in drosophila melanogaster. *Science*. 1978;200:1448–59.
229. Vidal M, Cagan RL. Drosophila models for cancer research. *Curr Opin Genet Dev*. 2006;16:10–6.
230. Gateff E. The genetics and epigenetics of neoplasms in drosophila. *Biol Rev Camb Philos Soc*. 1978;53:123–68.
231. Baonza A, Freeman M. Control of cell proliferation in the drosophila eye by Notch signaling. *Dev Cell*. 2005;8:529–39.
232. Cordero JB, Stefanatos RK, Scopelliti A, Vidal M, Sansom OJ. Inducible progenitor-derived wingless regulates adult midgut regeneration in drosophila. *EMBO J*. 2012;31:3901–17.
233. Kimble J, Nüsslein-Volhard C. The great small organisms of developmental genetics: caenorhabditis elegans and drosophila melanogaster. *Dev Biol*. 2022;485:93–122.
234. Miles WO, Dyson NJ, Walker JA. Modeling tumor invasion and metastasis in drosophila. *Dis Models Mech*. 2011;4:753–61.
235. Jiang H, Edgar BA. Intestinal stem cell function in drosophila and mice. *Curr Opin Genet Dev*. 2012;22:354–60.
236. Jiang H, et al. Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the drosophila midgut. *Cell*. 2009;137:1343–55.
237. Antonello ZA, Reiff T, Dominguez M. Mesenchymal to epithelial transition during tissue homeostasis and regeneration: patching up the drosophila midgut epithelium. *Fly*. 2015;9:132–7.
238. Antonello ZA, Reiff T, Ballesta-Illan E, Dominguez M. Robust intestinal homeostasis relies on cellular plasticity in enteroblasts mediated by miR-8–Escargot switch. *EMBO J*. 2015;34:2025–41.
239. Reiff T, et al. Notch and EGFR regulate apoptosis in progenitor cells to ensure gut homeostasis in drosophila. *EMBO J*. 2019;38:e101346.
240. Martorell O, et al. Conserved mechanisms of tumorigenesis in the drosophila adult midgut. *PLoS ONE*. 2014;9:e88413.
241. Quintero M, Bangi E. Disruptions in cell fate decisions and transformed enteroendocrine cells drive intestinal tumorigenesis in drosophila. *Cell Rep*. 2023;42:113370.
242. Gulubova M, Vlaykova T, Chromogranin A-, serotonin-, synaptophysin- and vascular endothelial growth factor-positive endocrine cells and the prognosis of colorectal cancer: an immunohistochemical and ultrastructural study. *J Gastroenterol Hepatol*. 2008;23:1574–85.
243. Hodge RA, et al. The septate junction component bark beetle is required for drosophila intestinal barrier function and homeostasis. *iScience*. 2023;26:106901.
244. Tian A, Benchabane H, Wang Z, Ahmed Y. Regulation of stem cell proliferation and cell fate specification by Wingless/Wnt signaling gradients enriched at adult intestinal compartment boundaries. *PLoS Genet*. 2016;12:e1005822.
245. Wilcockson SG, Guglielmi L, Araguas Rodriguez P, Amoyel M, Hill CS. An improved Erk biosensor detects oscillatory Erk dynamics driven by mitotic erasure during early development. *Dev Cell*. 2023;58:2802–e28185.
246. Zipper L, Corominas-Murtra B, Reiff T. Steroid hormone-induced wingless ligands tune female intestinal size in drosophila. *Nat Commun*. 2025;16:436.
247. Baonza A, Garcia-Bellido A. Notch signaling directly controls cell proliferation in the drosophila wing disc. *Proc Natl Acad Sci U S A*. 2000;97:2609–14.
248. Bach EA, et al. GFP reporters detect the activation of the drosophila JAK/STAT pathway in vivo. *Gene Expr Patterns*. 2007;7:323–31.
249. Karim FD, Rubin GM. Ectopic expression of activated Ras1 induces hyperplastic growth and increased cell death in drosophila imaginal tissues. *Development*. 1998;125:1–9.
250. Adams J, Casali A, Campbell K. Methods to generate and assay for distinct stages of cancer metastasis in adult drosophila melanogaster. In: Campbell K, Theveneau E, editors. *The Epithelial-to-mesenchymal transition: methods and protocols*. Springer US; 2021. pp. 161–70. https://doi.org/10.1007/978-1-0716-0779-4_14.
251. Adams J, Casali A, Campbell K. Sensitive High-Throughput assays for tumour burden reveal the response of a drosophila melanogaster model of colorectal cancer to standard chemotherapies. *Int J Mol Sci*. 2021;22:5101.
252. Campbell K, et al. Collective cell migration and metastases induced by an epithelial-to-mesenchymal transition in drosophila intestinal tumors. *Nat Commun*. 2019;10:2311.
253. Qin JY, et al. Systematic comparison of constitutive promoters and the Doxycycline-Inducible promoter. *PLoS ONE*. 2010;5:e10611.
254. Herranz H, Hong X, Cohen SM. Mutual repression by bantam miRNA and capicua links the EGFR/MAPK and Hippo pathways in growth control. *Curr Biol*. 2012;22:651–7.
255. Caussinus E, Gonzalez C. Induction of tumor growth by altered stem-cell asymmetric division in drosophila melanogaster. *Nat Genet*. 2005;37:1125–9.
256. Reiff T, Zipper L, Ramon-Cañellas P, Akkas F. Frazzled/DCC Directs Intestinal Progenitor Homing in Homeostasis and Metastasis. (2025). Preprint at <https://doi.org/10.21203/rs.3.rs-5078908/v1>
257. Richardson HE, Willoughby L, Humbert PO. Screening for Anti-cancer Drugs in Drosophila. *eLS* 1–14 (2015) <https://doi.org/10.1002/9780470015902.a0022535>
258. Su TT. Drug screening in Drosophila; why, when, and when not? *Wires Dev Biol*. 2019;8:e346.
259. Gladstone M, Su TT. Chemical genetics and drug screening in drosophila cancer models. *J Genet Genomics*. 2011;38:497–504.
260. Bangi E, et al. A personalized platform identifies Trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. *Sci Adv*. 2019;5:eaav6528.
261. Strange K. Drug discovery in Fish, Flies, and worms. *ILAR J*. 2016;57:133–43.
262. Bangi E, Murgia C, Teague AGS, Sansom OJ, Cagan RL. Functional exploration of colorectal cancer genomes using drosophila. *Nat Commun*. 2016;7:13615.
263. Baonza A, Tur-Gracia S, Pérez-Aguilera M, Estella C. Regulation and coordination of the different DNA damage responses in drosophila. *Front Cell Dev Biol*. 2022;10:993257. <https://doi.org/10.3389/fcell.2022.993257>.
264. van Bergeijk P, Heimiller J, Uyetake L, Su TT. Genome-wide expression analysis identifies a modulator of ionizing radiation-induced p53-independent apoptosis in drosophila melanogaster. *PLoS ONE*. 2012;7:e36539.
265. Porrazzo A, et al. DNA repair in tumor radioresistance: insights from fruit flies genetics. *Cell Oncol (Dordr)*. 2024;47:717–32.
266. Tassetto M, Kunitomi M, Andino R. Circulating immune cells mediate a systemic RNAi-based adaptive antiviral response in drosophila. *Cell*. 2017;169:314–e32513.
267. Kounatidis I, Ligoxygakis P. Drosophila as a model system to unravel the layers of innate immunity to infection. *Open Biology*. 2012;2:120075.
268. Brutscher F, Germani F, Hausmann G, Jutz L, Basler K. Activation of the drosophila innate immune system accelerates growth in Cooperation with oncogenic Ras. *PLoS Biol*. 2025;23:e3003068.
269. Bangi E, Pitsouli C, Rahme LG, Cagan R, Apidianakis Y. Immune response to bacteria induces dissemination of Ras-activated drosophila hindgut cells. *EMBO Rep*. 2012;13:569–76.
270. Mishra AK et al. Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing. *Proceedings of the National Academy of Sciences* 120, e2310221120 (2023).
271. Bangi E, et al. A drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma. *iScience*. 2021;24:102212.
272. Dietzl G, et al. A genome-wide Transgenic RNAi library for conditional gene inactivation in drosophila. *Nature*. 2007;448:151–6.
273. Bassett AR, Tibbit C, Ponting CP, Liu J-L. Highly efficient targeted mutagenesis of drosophila with the CRISPR/Cas9 system. *Cell Rep*. 2013;4:220–8.
274. Markstein M, et al. Systematic screen of chemotherapeutics in drosophila stem cell tumors. *Proc Natl Acad Sci U S A*. 2014;111:4530–5.
275. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. *Cancer Res*. 2005;65:3538–41.
276. Zipper L, Batchu S, Kaya NH, Antonello ZA, Reiff T. The MicroRNA miR-277 controls physiology and pathology of the adult drosophila midgut by

- regulating the expression of fatty acid β -Oxidation-Related genes in intestinal stem cells. *Metabolites*. 2022;12:315.
277. Bosch JA, Birchak G, Perrimon N. Precise genome engineering in *Drosophila* using prime editing. *Proc Natl Acad Sci*. 2021;118(1):e2021996118. <https://doi.org/10.1073/pnas.2021996118>.
278. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974;77:71–94.
279. Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, *Caenorhabditis elegans*. *Dev Biol*. 1977;56:110–56.
280. Sulston JE, Schierenberg E, White JG, Thomson J. N. The embryonic cell lineage of the nematode *Caenorhabditis elegans*. *Dev Biol*. 1983;100:64–119.
281. Horvitz HR. Genetic control of programmed cell death in the nematode *Caenorhabditis elegans*. *Cancer Res*. 1999;59:1701–6.
282. Hengartner MO, Horvitz HR. C. elegans cell survival gene *ced-9* encodes a functional homolog of the mammalian proto-oncogene *bcl-2*. *Cell*. 1994;76:665–76.
283. Gumienny TL, Lambie E, Hartwig E, Horvitz HR, Hengartner MO. Genetic control of programmed cell death in the *Caenorhabditis elegans* hermaphrodite germline. *Development*. 1999;126:1011–22.
284. Gartner A, Milstein S, Ahmed S, Hodgkin J, Hengartner MO. A conserved checkpoint pathway mediates DNA Damage–Induced apoptosis and cell cycle arrest in *C. elegans*. *Mol Cell*. 2000;5:435–43.
285. Derry WB, Putzke AP, Rothman JH. *Caenorhabditis elegans* p53: role in Apoptosis, Meiosis, and stress resistance. *Science*. 2001;294:591–5.
286. Schumacher B, Hofmann K, Boulton S, Gartner A. The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. *Curr Biol*. 2001;11:1722–7.
287. Chen X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. *Cell Death Dis*. 2022;13:974.
288. Schumacher B, et al. C. elegans *ced-13* can promote apoptosis and is induced in response to DNA damage. *Cell Death Differ*. 2005;12:153–61.
289. Schumacher B, et al. Translational repression of *C. elegans* p53 by *GLD-1* regulates DNA Damage–Induced apoptosis. *Cell*. 2005;120:357–68.
290. Ou H-L, Kim CS, Uszkoreit S, Wickström SA, Schumacher B. Somatic niche cells regulate the CEP-1/p53-Mediated DNA damage response in primordial germ cells. *Dev Cell*. 2019;50:167–e1838.
291. Gao MX, et al. The SCFFSN-1 ubiquitin ligase controls germline apoptosis through CEP-1/p53 in *C. elegans*. *Cell Death Differ*. 2008;15:1054–62.
292. Fernández-Majada V, et al. The tumour suppressor *CYLD* regulates the p53 DNA damage response. *Nat Commun*. 2016;7:12508.
293. Ackermann L, et al. E4 ligase-specific ubiquitination hubs coordinate DNA double-strand-break repair and apoptosis. *Nat Struct Mol Biol*. 2016;23:995–1002.
294. Beitel GJ, Tuck S, Greenwald I, Horvitz HR. The *Caenorhabditis elegans* gene *lin-1* encodes an ETS-domain protein and defines a branch of the vulval induction pathway. *Genes Dev*. 1995;9:3149–62.
295. Han M, Sternberg PW. *let-60*, a gene that specifies cell fates during *C. elegans* vulval induction, encodes a Ras protein. *Cell*. 1990;63:921–31.
296. Lackner MR, Kornfeld K, Miller LM, Horvitz HR, Kim SK. A MAP kinase homolog, *mpk-1*, is involved in ras-mediated induction of vulval cell fates in *Caenorhabditis elegans*. *Genes Dev*. 1994;8:160–73.
297. Francis R, Maine E, Schedl T. Analysis of the multiple roles of *gld-1* in germline development: interactions with the sex determination cascade and the *gld-1* signaling pathway. *Genetics*. 1995;139:607–30.
298. Jones AR, Schedl T. Mutations in *gld-1*, a female germ cell-specific tumor suppressor gene in *Caenorhabditis elegans*, affect a conserved domain also found in Src-associated protein Sam68. *Genes Dev*. 1995;9:1491–504.
299. Friedland AE, et al. Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nat Methods*. 2013;10:741–3.
300. Dickinson DJ, Goldstein B. CRISPR-Based methods for *Caenorhabditis elegans* genome engineering. *Genetics*. 2016;202:885–901.
301. Firnhaber C, Hammarlund M. Neuron-specific feeding RNAi in *C. elegans* and its use in a screen for essential genes required for GABA neuron function. *PLoS Genet*. 2013;9:e1003921.
302. Hobert O. The impact of whole genome sequencing on model system genetics: get ready for the ride. *Genetics*. 2010;184:317–9.
303. Fraser AG, et al. Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature*. 2000;408:325–30.
304. Fire A, et al. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature*. 1998;391:806–11.
305. Arribere JA, et al. Efficient Marker-Free recovery of custom genetic modifications with CRISPR/Cas9 in *Caenorhabditis elegans*. *Genetics*. 2014;198:837–46.
306. Sato Y, et al. Clinical possibility of *Caenorhabditis elegans* as a novel evaluation tool for esophageal cancer patients receiving chemotherapy: A prospective study. *Cancers (Basel)*. 2023;15:3870.
307. Mello C, Fire A. Chapter 19 DNA transformation. In: Epstein HF, Shakes DC, editors. *Methods in cell biology*. Volume 48. Academic; 1995. pp. 451–82.
308. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. *Science*. 1994;263:802–5.
309. Powers JA. Live-cell imaging of mitosis in *Caenorhabditis elegans* embryos. *Methods*. 2010;51:197–205.
310. Zhou Z, Hartwig E, Horvitz HR. *CED-1* is a transmembrane receptor that mediates cell corpse engulfment in *C. elegans*. *Cell*. 2001;104:43–56.
311. Lant B, Derry WB. Methods for detection and analysis of apoptosis signaling in the *C. elegans* germline. *Methods*. 2013;61:174–82.
312. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell*. 1986;44:817–29.
313. Lans H, et al. Involvement of global genome Repair, transcription coupled Repair, and chromatin remodeling in UV DNA damage response changes during development. *PLoS Genet*. 2010;6:e1000941.
314. Ermolaeva MA, et al. DNA damage in germ cells induces an innate immune response that triggers systemic stress resistance. *Nature*. 2013;501:416–20.
315. Wolters S, et al. Loss of *Caenorhabditis elegans* BRCA1 promotes genome stability during replication in *smc-5* mutants. *Genetics*. 2014;196:985–99.
316. Lans H, Vermeulen W. Nucleotide excision repair in *Caenorhabditis elegans*. *Mol Biol Int*. 2011;2011:542795. <https://doi.org/10.4061/2011/542795>.
317. Jaramillo-Lambert A, Ellefson M, Villeneuve AM, Engebrecht J. Differential timing of S phases, X chromosome replication, and meiotic prophase in the *C. elegans* germ line. *Dev Biol*. 2007;308:206–21.
318. Stergiou L, Doukoumetzidis K, Sandoel A, Hengartner MO. The nucleotide excision repair pathway is required for UV-C-induced apoptosis in *Caenorhabditis elegans*. *Cell Death Differ*. 2007;14:1129–38.
319. Crittenden SL, Leonhard KA, Byrd DT, Kimble J. Cellular analyses of the mitotic region in the *Caenorhabditis elegans* adult germ line. *Mol Biol Cell*. 2006;17:3051–61.
320. Misare KR, et al. The consequences of tetraploidy on *Caenorhabditis elegans* physiology and sensitivity to chemotherapeutics. *Sci Rep*. 2023;13:18125.
321. Wit J, et al. Praziquantel inhibits *Caenorhabditis elegans* development and species-wide differences might be cct-8-dependent. *PLoS ONE*. 2023;18:e0286473.
322. García-González AP, et al. Bacterial metabolism affects the *C. elegans* response to cancer chemotherapeutics. *Cell*. 2017;169:431–e4418.
323. Giunti S, Andersen N, Rayes D, De Rosa MJ. Drug discovery: insights from the invertebrate *Caenorhabditis elegans*. *Pharmacol Res Perspect*. 2021;9:e00721.
324. Xiong H, Pears C, Woollard A. An enhanced *C. elegans* based platform for toxicity assessment. *Sci Rep*. 2017;7:9839.
325. Cerón J. *Caenorhabditis elegans* for research on cancer hallmarks. *Dis Model Mech*. 2023;16:dmm050079.
326. Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. *Br J Cancer*. 2019;121:101–8.
327. Cidre-Aranaz F et al. *clAP1* inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma. Preprint at <https://doi.org/10.1101/2025.06.27.661947> (2025).
328. Day C-P, Merlino G, Van Dyke T. Preclinical mouse cancer models: A maze of opportunities and challenges. *Cell*. 2015;163:39–53.
329. Chuprin J, et al. Humanized mouse models for immuno-oncology research. *Nat Rev Clin Oncol*. 2023;20:192–206.
330. Antonica F, et al. Modeling brain tumors: A perspective overview of in vivo and organoid models. *Front Mol Neurosci*. 2022;15:818696. <https://doi.org/10.3389/fnmol.2022.818696>.
331. Deycar S, Gomes B, Charo J, Ceppi M, Cline JM. Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy. *J Immunother Cancer*. 2023;11(1):e005514. <https://doi.org/10.1136/jitc-2022-005514>.
332. Power EA, et al. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic Pontine glioma. *PLoS ONE*. 2022;17:e0263822.
333. Kobet RA, et al. *Caenorhabditis elegans*: A model system for Anti-Cancer drug discovery and therapeutic target identification. *Biomol Ther (Seoul)*. 2014;22:371–83.

334. O'Reilly LP, Luke CJ, Perlmutter DH, Silverman GA, Pak S. C. C. elegans in high-throughput drug discovery. *Adv Drug Deliv Rev.* 2014;0:247–53.
335. Hidalgo M, et al. Patient derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov.* 2014;4:998–1013.
336. Bhimani J, Ball K, Stebbing J. Patient-derived xenograft models—the future of personalised cancer treatment. *Br J Cancer.* 2020;122:601–2.
337. Gao Y, et al. Patient-Derived xenograft models for intrahepatic cholangiocarcinoma and their application in guiding personalized medicine. *Front Oncol.* 2021;11:704042. <https://doi.org/10.3389/fonc.2021.704042>.
338. Ogilvie LA, Kovachev A, Wierling C, Lange BMH, Lehrach H. Models of models: A translational route for cancer treatment and drug development. *Front Oncol.* 2017;7:219. <https://doi.org/10.3389/fonc.2017.00219>.
339. Al-Kabani A, et al. Exploring experimental models of colorectal cancer: A critical appraisal from 2D cell systems to Organoids, humanized mouse Avatars, Organ-on-Chip, CRISPR Engineering, and AI-Driven Platforms-Challenges and opportunities for translational precision oncology. *Cancers (Basel).* 2025;17:2163.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.